



(51) International Patent Classification:

C07D 221/20 (2006.01) A61P 25/00 (2006.01)
A61K 31/438 (2006.01) A61P 25/16 (2006.01)

(21) International Application Number:

PCT/CA2014/051252

(22) International Filing Date:

22 December 2014 (22.12.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/920,160 23 December 2013 (23.12.2013) US
62/005,196 30 May 2014 (30.05.2014) US

(71) Applicant: **ALECTOS THERAPEUTICS INC.**
[CA/CA]; 8999 Nelson Way, Burnaby, British Columbia
V5A 4B5 (CA).

(72) Inventors: **KAUL, Ramesh**; c/o Alectos Therapeutics Inc.,
8999 Nelson Way, Burnaby, British Columbia V5A 4B5
(CA). **MCEACHERN, Ernest J.**; c/o Alectos Therapeut-
ics Inc., 8999 Nelson Way, Burnaby, British Columbia
V5A 4B5 (CA). **SUN, Jianyu**; c/o Alectos Therapeutics
Inc., 8999 Nelson Way, Burnaby, British Columbia V5A
4B5 (CA). **VOCADLO, David J.**; c/o Alectos Therapeut-
ics Inc., 8999 Nelson Way, Burnaby, British Columbia
V5A 4B5 (CA). **ZHOU, Yuanxi**; c/o Alectos Therapeutics
Inc., 8999 Nelson Way, Burnaby, British Columbia V5A
4B5 (CA). **ZHU, Yongbao**; c/o Alectos Therapeutics Inc.,

8999 Nelson Way, Burnaby, British Columbia V5A 4B5
(CA).

(74) Agents: **CHATTERJEE, Alakananda** et al.; Borden Lad-
ner Gervais LLP, 100 Queen Street, Suite 1300, Ottawa,
Ontario K1P 1J9 (CA).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: GLUCOCEREBROSIDASE MODULATORS AND USES THEREOF



(57) Abstract: The invention provides isofogamine analogs of structural formula (I) below that modulate and stabilize gluco-
cerebrosidases and enhance their enzymatic activity *in vivo*. Such compounds, prodrugs and compositions thereof are useful in treat-
ing synucleinopathy, lysosomal storage disease and relevant neurodegenerative disease.

GLUCOCEREBROSIDASE MODULATORS AND USES THEREOF

FIELD OF THE INVENTION

[0001] This application relates in part to compounds which modulate glycosidases and uses thereof.

BACKGROUND OF THE INVENTION

[0002] A defining pathological feature of Parkinson's disease (PD) is the abnormal accumulation of alpha-synuclein protein deposits within the brain into what are known as Lewy bodies. The accumulation of alpha-synuclein within the brain leads to the progressive death of dopaminergic neurons and downstream cognitive and behavioral impairments. In addition to PD, aggregation of alpha-synuclein is also associated with a broad group of neurodegenerative diseases known collectively as synucleopathies; examples include dementia with Lewy bodies, multiple system atrophy, Pick's disease, and corticobasal degeneration. Similarly, alpha-synuclein protein deposits and Lewy bodies are often associated with the development of Alzheimer's disease.¹ Augmentation of β -glucocerebrosidase (GCase, EC. 3.2.1.45) activity in a mouse model of PD has been implicated in reduced alpha-synuclein accumulation and delayed onset of pathology.²⁻⁵ In addition, small-molecule GCase modulators have been shown to reduce alpha-synuclein levels and behavioural deficits in a rodent model of PD.^{6,7}

[0003] Gaucher's disease (GD) is a lysosomal storage disorder caused by homozygous loss of function mutations in *GBA1*, the gene encoding GCase.⁸ Normally, GCase present within lysosomes catalyzes hydrolytic cleavage of glucose from the glycolipid glucocerebroside (also known as glucosylceramide) within this compartment of cells. In Gaucher's disease, lysosomal GCase levels are greatly reduced or functionally absent, leading to the pathological accumulation of glucosylceramide within lysosomes. Symptoms of Gaucher's disease may include some or all of the following: enlarged spleen and liver; liver malfunction; skeletal disorders and bone lesions that may be painful; severe neurologic complications; swelling of lymph nodes and (occasionally) adjacent joints; distended abdomen; a brownish tint to the skin; anemia; low blood platelets and yellow fatty deposits on the sclera. In addition, persons affected with Gaucher's disease may be more susceptible to various infections. Current

treatment of Gaucher's involves administering recombinant human GCCase as an enzyme replacement therapy (ERT), which helps to control the visceral and haematological complications of Gaucher's disease. However, because the recombinant enzyme is not brain-penetrant, ERT does not improve the neurological manifestations of the disease.


5 [0004] International patent applications PCT/US2004/037704, filed 12 November 2004, published under No. WO 2005/046612 on 26 May 2005; PCT/US2007/072016, filed 25 June 2007, published under No. WO 2007/150064 on 27 December 2007; PCT/US2010/030470, filed 9 April 2010, published under No. WO 2010/118282 on 14 October 2010; PCT/US2010/051447, filed 5 October 2010, published under No. WO 2011/049736 on 28
10 April 2011; PCT/US2010/051458, filed 5 October 2010, published under No. WO 2011/049737 on 28 April 2011; PCT/CA2012/001084, filed 23 November 2012, published under No. WO 2013/075227 on 30 May 2013; PCT/US2013/029612, filed 7 March 2013, published under No. WO 2013/148103 on 3 October 2013, are directed to small-molecule modulators of GCCase.

15

SUMMARY OF THE INVENTION

[0005] The invention provides, in part, compounds for modulating glycosidases, prodrugs of the compounds, uses of the compounds and the prodrugs, pharmaceutical compositions including the compounds or prodrugs of the compounds, and methods of treating diseases and
20 disorders related to deficiency or overexpression of GCCase, and/or accumulation or deficiency of glucosylceramide. In some embodiments, the invention provides compositions and methods to prevent and/or treat a neurodegenerative disease, including Parkinson's disease and Alzheimer's disease, or a lysosomal storage disorder, including Gaucher's disease, by administering to a patient in need thereof an effective amount of one or more of
25 the compounds or prodrugs of the compounds described herein.

[0006] In one aspect, the invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof:




(I)

where R^1 may be OH and R^2 may be H or methyl; or R^1 may be F and R^2 may be H or F; or R^1 may be H and R^2 may be F; R^3 may be: C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{3-8} cycloalkyl, C_{4-10} cycloalkylalkyl, C_{2-10} alkoxyalkyl, C_{7-15} arylalkyl, or C_{2-15} heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH_3 , and/or OH; or R^3 may be CN, CO_2H , $C(O)NHCH_3$, or $C(O)NH(\text{cyclopropyl})$; and R^4 may be: H or C_{1-10} alkyl, the C_{1-10} alkyl optionally substituted from one up to the maximum number of substituents with F and/or OH.

5

10

[0007] In alternative embodiments, the invention provides a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof:



(Ia)


where R^1 may be OH and R^2 may be H or methyl; or R^1 may be F and R^2 may be H or F; or R^1 may be H and R^2 may be F; R^3 may be $C(R^5)(R^6)(R^7)$, where R^5 may be: H, OH, F, Cl, and C_{1-10} alkyl, the C_{1-10} alkyl optionally substituted from one up to the maximum number of substituents with one or more of fluoro and/or OH; R^6 and R^7 may independently be: H, F, C_{1-10} alkyl, C_{3-8} cycloalkylmethyl, aryl, or heteroaryl, each excluding H and F optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH or methyl; or R^6 and R^7 may be connected together with the carbon atom to which they are attached to form a ring, the ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl; and R^4 may be: H, C_{1-10} alkyl, the C_{1-10} alkyl optionally substituted from one up to the maximum number of substituents with fluoro and/or OH; where when R^5 is OH, then R^6 and R^7 are other than F.

15

20

25


[0008] In alternative embodiments, the invention provides a compound of Formula (Ib) or a pharmaceutically acceptable salt thereof:



(Ib)

where R³ may be: C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, C₃₋₈ cycloalkyl, C₄₋₁₀ cycloalkylalkyl, C₂₋₁₀ alkoxyalkyl, C₇₋₁₅ arylalkyl, or C₂₋₁₅ heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH₃, and/or OH; or R³ may be CN, CO₂H, C(O)NHCH₃, or C(O)NH(cyclopropyl).


[0009] In alternative embodiments, the invention provides a compound of Formula (Ic) or a pharmaceutically acceptable salt thereof:



(Ic)

where R³ may be: C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, C₃₋₈ cycloalkyl, C₄₋₁₀ cycloalkylalkyl, C₂₋₁₀ alkoxyalkyl, C₇₋₁₅ arylalkyl, or C₂₋₁₅ heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH₃, and/or OH; or R³ may be CN, CO₂H, C(O)NHCH₃, or C(O)NH(cyclopropyl).


[0010] In alternative embodiments, the invention provides a compound of Formula (Id) or a pharmaceutically acceptable salt thereof:



(Id)

where R³ may be: C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, C₃₋₈ cycloalkyl, C₄₋₁₀ cycloalkylalkyl, C₂₋₁₀ alkoxyalkyl, C₇₋₁₅ arylalkyl, or C₂₋₁₅ heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH₃, and/or OH; or R³ may be CN, CO₂H, C(O)NHCH₃, or C(O)NH(cyclopropyl).


[0011] In alternative embodiments, the invention provides a compound of Formula (Ie) or a pharmaceutically acceptable salt thereof:



(Ie)

where R³ may be: C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, C₃₋₈ cycloalkyl, C₄₋₁₀ cycloalkylalkyl, C₂₋₁₀ alkoxyalkyl, C₇₋₁₅ arylalkyl, or C₂₋₁₅ heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH₃, and/or OH; or R³ may be CN, CO₂H, C(O)NHCH₃, or C(O)NH(cyclopropyl).

[0012] In alternative embodiments, the invention provides a compound of Formula (If) or a pharmaceutically acceptable salt thereof:



(If)

where R⁸ may be H or C₁₋₁₀ alkyl, the C₁₋₁₀ alkyl optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH₃, and/or OH.

[0013] In alternative embodiments, the compound may be a prodrug; the compound may modulate a β -glucocerebrosidase (GCCase); the compound may bind to a GCCase (e.g., a mammalian GCCase); the compound may bind to a wild-type GCCase; the compound may bind

to a mutant GCCase; the compound may increase protein levels of a GCCase; the compound may increase activity levels of a GCCase.


[0014] In alternative embodiments, a compound according to Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), or Formula (If) may have enhanced permeability.

[0015] In alternative embodiments, a compound according to Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), or Formula (If) may have enhanced permeability.

[0016] In alternative embodiments, a compound according to Formula (If) may have enhanced permeability.

[0017] In alternative aspects, the invention provides a pharmaceutical composition including a compound according to the invention, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

[0018] In alternative aspects, the invention provides methods of modulating a GCCase in a subject in need thereof, or of increasing the level of GCCase in a subject in need thereof, or of increasing the activity of GCCase in a subject in need thereof, or of treating a neurodegenerative disease, or a lysosomal storage disease, in a subject in need thereof, by administering to the subject an effective amount of a compound of Formula (I), including any one or more of Formula (Ia) - (If), or a pharmaceutically acceptable salt thereof:




(I)

where R^1 may be OH and R^2 may be H or methyl; or R^1 may be F and R^2 may be H or F; or R^1 may be H and R^2 may be F; R^3 may be: C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{3-8} cycloalkyl, C_{4-10} cycloalkylalkyl, C_{2-10} alkoxyalkyl, C_{7-15} arylalkyl, or C_{2-15} heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH_3 , and/or OH; or R^3 may be CN, CO_2H , $C(O)NHCH_3$, or $C(O)NH(cyclopropyl)$; and R^4 may be: H, C_{1-10} alkyl, the C_{1-10} alkyl optionally substituted from one up to the maximum number of substituents with F and/or OH.

The neurodegenerative disease may be Parkinson's disease, Dementia with Lewy bodies, Multiple system atrophy, Pick's disease (PiD), Corticobasal degeneration (CBD), Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Amyotrophic lateral sclerosis with cognitive impairment (ALSci), Argyrophilic grain dementia, Bluit disease, Dementia pugilistica, Diffuse neurofibrillary tangles with calcification, Down's syndrome, Familial British dementia, Familial Danish dementia, Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Gerstmann-Straussler-Scheinker disease, Guadeloupean parkinsonism, Hallevorden-Spatz disease (neurodegeneration with brain iron accumulation type 1), Myotonic dystrophy, Multi-infarct dementia, Niemann-Pick disease (type C), Pallido-ponto-nigral degeneration, Parkinsonism-dementia complex of Guam, Post-encephalitic parkinsonism (PEP), Prion diseases (including Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (vCJD), Fatal Familial Insomnia, and Kuru), Progressive supercortical gliosis, Progressive supranuclear palsy (PSP), Richardson's syndrome, Subacute sclerosing panencephalitis, Tangle-only dementia, Huntington's disease, Schizophrenia, Mild Cognitive Impairment (MCI), Neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, and diabetic neuropathy), or Glaucoma. The lysosomal storage disease may be Gaucher's disease, including Type I, Type II, and Type III Gaucher's disease.

[0019] In alternative embodiments, the administering may increase the level of GCase in the subject. The subject may be a human.

[0020] In alternative aspects, the invention provides use of a compound of an effective amount of a compound of Formula (I), including any one or more of Formula (Ia) - (If), or a pharmaceutically acceptable salt thereof:



25

(I)

where R¹ may be OH and R² may be H or methyl; or R¹ may be F and R² may be H or F; or R¹ may be H and R² may be F; R³ may be: C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, C₃₋₈ cycloalkyl, C₄₋₁₀ cycloalkylalkyl, C₂₋₁₀ alkoxyalkyl, C₇₋₁₅ arylalkyl, or C₂₋₁₅

heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH₃, and/or OH; or R³ may be CN, CO₂H, C(O)NHCH₃, and C(O)NH(cyclopropyl); and R⁴ may be: H, C₁₋₁₀ alkyl, the C₁₋₁₀ alkyl optionally substituted from one up to the maximum number of substituents with F and/or OH,
5 in the preparation of a medicament. The medicament may be for modulating a GCase, for increasing the level of GCase, for increasing the activity of GCase, for treating a condition modulated by a GCase, for treating a neurodegenerative disease or a lysosomal storage disease.

[0021] In alternative aspects, the invention provides methods of synthesis to prepare a
10 compound as described herein, or a pharmaceutically acceptable salt thereof.

[0022] This summary of the invention does not necessarily describe all features of the invention.

DETAILED DESCRIPTION

15 [0023] The invention provides, in part, compounds for modulating a β -glucocerebrosidase (GCase) and uses thereof.

[0024] By a “ β -glucocerebrosidase” or “GCase” is meant an enzyme with glucosylceramidase activity (EC 3.2.1.45) that catalyzes the hydrolytic cleavage of the beta-glucosidic linkage of the glycolipid glucocerebroside (also known as glucosylceramide).
20 Alternative names for a GCase include: acid beta-glucosidase, beta-GC, glucosylceramidase, GlcCerase, D-glucosyl-N-acylsphingosine glucohydrolase, GBA, GBA1, GBA2, and GBA3. In some embodiments, the GCase may be a mammalian GCase, such as a rat, mouse or human GCase. The GCase may be a wild-type GCase or a mutant GCase. In some
25 embodiments, the GCase may be a wild-type mammalian GCase, such as a rat, mouse or human wild-type GCase. In some embodiments, the GCase may be a mutant mammalian GCase, such as a rat, mouse or human mutant GCase. In some embodiments, the GCase may be a human lysosomal GCase. In some embodiments, the GCase may be a human non-lysosomal GCase. In some embodiments, the GCase may be a human cytosolic GCase. In
30 some embodiments, the GCase may have a sequence as set forth in any one of the following Accession numbers: P04062, Q9HCG7, Q9H227, P17439, P97265, Q69ZF3, Q5M868, Q70KH2, Q2KHZ8, Q5R8E3, or Q9BDT0. In alternative embodiments, the GCase may be encoded by a sequence as set forth in any one of the following Accession numbers:

NG_009783.1, NP_065995.1, NP_066024.1, NP_001121904.1, NP_001264154.1, NP_766280.2, NP_001121111.1, NP_001013109.2, NP_001005730.1, NM_001046421.2, NM_001134016.1, or NM_001008997.1. In alternative embodiments, the human GCCase may have the sequence set forth below:

```

5      10      20      30      40      50      60
      MEFSSPSREE  CPKPLSRVSI  MAGSLTGLLL  LQAVSWASGA  RPCIPKSFGY  SSVVVCVCNAT

      70      80      90      100     110     120
      YCDFSDPPTF  PALGTFSRYE  STRSGRRMEL  SMGPIQANHT  GTGLLLTLQP  EQKFQKVKGF

10     130     140     150     160     170     180
      GGAMTDAAAL  NILALSPPAQ  NLLLSYFSE  EGIGYNIIRV  PMASCDFSIR  TTYTADTPDD

      190     200     210     220     230     240
15     FQLHNFLPE  EDTKLKIPLI  HRALQLAQRP  VSLLASPWTS  PTWLKTNGAV  NGKSLKGP

      250     260     270     280     290     300
      GDIYHQTWAR  YFVKFLDAYA  EHKLQFWAVT  AENEPSAGLL  SGYPFQCLGF  TPEHQRDFIA

20     310     320     330     340     350     360
      RDLGPTLANS  THHNVRLLML  DDQRLLLPHW  AKVVLTDPEA  AKYVHGIAVH  WYLDFLAPAK

      370     380     390     400     410     420
      ATLGETHRLF  PNTMLFASEA  CVGSKFWEQS  VRLGSWDRGM  QYSHSIITNL  LYHVVGWTDW

25     430     440     450     460     470     480
      NLALNPEGGP  NWVRNFVDSP  IIVDITKDTF  YKQPMFYHLG  HFSKFIPEGS  QRVGLVASQK

      490     500     510     520     530
30     NDLDAVLMH  PDGSAVVVVL  NRSSKDVPLT  IKDPAVGFLE  TISPGYSIHT  YLWRRQ (SEQ ID
      NO: 1)

```

[0025] In alternative embodiments, the human GCCase may have the nucleic acid sequence of a nucleic acid molecule encoding the sequence set forth in SEQ ID NO: 1.

35 [0026] Examples of mutant human GCCase may include mutant enzymes bearing the *N370S* allele (mutant GCCase sequence: QSVRLGSWDRGMQYSHSIITSLLYHVVGWTDWNLALNPEGG; SEQ ID NO: 2), the *L444P* allele (mutant GCCase sequence: SKFIPEGSQRVGLVASQKNDPDAVALMHDPGSAVVVVLNRS; SEQ ID NO: 3), the *F213I* allele (mutant GCCase sequence: GK^GSLK^GQPGDIYH^QTWARYIVKFLDAYAEHKLQFWAVTAE; SEQ ID NO: 4), the *G202R* allele (mutant GCCase sequence: PTWLKTNGAVNGK^GSLK^GQPRDIYH^QTWARYFVKFLDAYAE; SEQ ID NO: 5), or other mutant alleles.⁹

[0027] In some embodiments, one or more of the compounds according to the invention may modulate a GCase. By “modulate” or “modulating,” as used herein, is meant changing, by either increase or decrease. Accordingly, a “modulatory compound”, as used herein, includes any compound capable of either changing GCase expression (*e.g.*, at the level of transcription, translation, or post-translation) or protein activity or biological function.

[0028] In some embodiments, one or more of the compounds according to the invention may inhibit the activity of a GCase, for example, the ability to inhibit the cleavage of glucose from glucosylceramide or the ability to inhibit the cleavage of glucose from a suitable substrate molecule such as, for example, 4-methylumbelliferone- β -D glucopyranoside. By “inhibit,” “inhibition” or “inhibiting” means a decrease by any value between about 10% and about 90%, or of any value between about 30% and about 60%, or over about 100%, or a decrease by about 1-fold, 2-fold, 5-fold, 10-fold or more, in comparison to a reference sample or compound, or in comparison to a wild type GCase. It is to be understood that the inhibiting does not require full inhibition. In some embodiments, the inhibition may be transient. For example, one or more of the compounds according to the invention may inhibit a GCase within a specific cellular compartment, such as the endoplasmic reticulum or Golgi apparatus, but may dissociate and no longer inhibit a GCase within another cellular compartment, for example a lysosomal compartment.

[0029] In some embodiments, one or more of the compounds according to the invention that inhibit the activity of a GCase may also stabilize the same enzyme. By “stabilization” is meant preventing denaturation, proteolysis, or degradation of the enzyme. In some embodiments, one or more of the compounds according to the invention may stabilize a GCase within a specific cellular compartment, such as the endoplasmic reticulum or Golgi apparatus. In some embodiments, one or more of the compounds according to the invention that exhibit stabilization of a GCase may enhance trafficking of the enzyme from the ER or Golgi through the secretory pathway to its proper cellular destination, for example, a lysosomal compartment. In some embodiments, one or more of the compounds according to the invention that enhance trafficking of a GCase to its proper cellular destination may dissociate from the enzyme once the enzyme reaches that destination, for example, a lysosomal compartment. In some embodiments, one or more compounds that exhibit stabilization of a GCase and enhance trafficking of a GCase may increase the protein level of a GCase, for example, in a lysosomal compartment. In some embodiments, one or more

compounds that increase the protein level of a GCCase may also increase the activity level of a GCCase, for example, in a lysosomal compartment.

[0030] In some embodiments, one or more of the compounds according to the invention may specifically bind a GCCase. In alternative embodiments, one or more of the compounds
5 according to the invention may specifically bind the active site of a GCCase. In some embodiments, one or more of the compounds according to the invention may specifically bind to allosteric sites, natural ligand binding sites, or other sites on a GCCase. In some
10 embodiments, one or more of the compounds according to the invention that specifically bind the active site of a GCCase may also inhibit the activity of a GCCase. In alternative embodiments, one or more of the compounds according to the invention may specifically bind a site other than the active site of a GCCase. In alternative embodiments, one or more of the compounds according to the invention may specifically bind one isoform of a GCCase, for example the human lysosomal GBA1 isoform. In alternative embodiments, one or more of the compounds according to the invention may specifically bind the human lysosomal GBA1
15 isoform of a GCCase over the human non-lysosomal GBA2 isoform and/or the human cytosolic GBA3 isoform. By “specifically binds” is meant a compound that binds a GCCase but does not substantially bind other molecules in a sample, such as a lactase, a sucrase, an isomaltase, a glucosylceramide synthase, an alpha-glucosidase II, a glycogen phosphorylase, an acid alpha-glucosidase, a beta-hexosaminidase, an O-GlcNAcase, or another GCCase
20 isoform. By “not substantially bind” is meant a binding specificity in the range of about 5-fold to about 100,000-fold, or about 10-fold to about 100,000-fold, or in the range of about 100-fold to about 100,000-fold, or in the range of about 1000-fold to about 100,000-fold, or at least about 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, 500-fold, 1000-fold, 1500-fold, 2000-fold, 2500-fold, 3000-fold, 3500-fold, 4000-fold, 4500-fold, 5000-fold, 6000-fold,
25 7000-fold, 10,000-fold, 25,000-fold, 50,000-fold, 75,000-fold, or any value within or about the described range, where “binding specificity” means the ratio of the respective binding constants, that is, $K_{i(\text{other molecule})}/K_{i\text{GCCase}}$.

[0031] In some embodiments, one or more compounds according to the invention may act as a pharmacological chaperone for a GCCase. A pharmacological chaperone, as used herein, is a
30 small molecule that may be useful to increase enzyme levels, as in pharmacological chaperone therapy or “PCT”.^{10,11} In PCT, a small molecule binds to an enzyme, such as a GCCase, in the endoplasmic reticulum (ER) or Golgi apparatus (Golgi) and enhances the ability of the enzyme to reach, and/or maintain, its proper fold. Compounds that are

pharmacological chaperones may be active-site inhibitors, but may also bind to other sites on the enzyme such as allosteric sites, natural ligand binding sites, or other sites. Without being bound to any particular hypothesis, binding of the chaperone to the enzyme may enhance its trafficking through the secretory pathway to its proper cellular destination, to allow the enzyme to carry out its normal functions. Accordingly, in some embodiments, administration of a compound as described herein, that is a pharmacological chaperone, may increase the lysosomal concentration and/or activity of a GCase. In some embodiments, a compound as described herein, may be used as a pharmacological chaperone to increase deficient or defective levels of a GCase. In alternative embodiments, a compound as described herein, may be used as a pharmacological chaperone to increase wild-type levels of a GCase. In some embodiments, an inhibitor that binds to a GCase may also act as a pharmacological chaperone for a GCase. In some embodiments, an inhibitor that acts as a pharmacological chaperone for a GCase may exhibit transient inhibition of a GCase. In some embodiments, an inhibitor that binds to a GCase and acts as a pharmacological chaperone for a GCase may dissociate from a GCase once the enzyme reaches its proper cellular destination (for example, the lysosomal compartment), so that the enzyme is no longer inhibited and is able to carry out its normal functions. In some embodiments, a compound as described herein, may be used as a pharmacological chaperone to increase the levels of a mutant GCase; in such situations, the mutant GCase in its properly folded state should have sufficient catalytic activity. In some embodiments, the GCase may be a chaperone-responsive mutant mammalian GCase, such as a rat, mouse or human mutant GCase. By a “chaperone-responsive mutant” is meant an enzyme (such as a GCase) bearing a mutation, the effects of which can be ameliorated by a compound that can act as a pharmacological chaperone for that mutant enzyme and thereby increase the concentration and/or activity level of that mutant enzyme. Chaperone-responsive GCase mutations include, without limitation, mutant GCase enzymes bearing mutations as set forth in, for example, SEQ ID NOs: 2, 3, 4, or 5.

[0032] In some embodiments, one or more compounds according to the invention may exhibit superior ability to act as a pharmacological chaperone for a GCase. In some embodiments, one or more compounds according to the invention may produce an increased enhancement of a GCase concentration and/or activity level compared to a suitable reference compound that is a pharmacological chaperone for a GCase. By “increased enhancement” means a greater enhancement of a GCase concentration and/or activity level by any value between about 10% and about 90%, or of any value between about 30% and about 60%, or

over about 100%, or an increase by about 1-fold, 2-fold, 5-fold, 10-fold or more, in comparison to the enhancement produced by a suitable reference compound that is a pharmacological chaperone for a GCCase. In some embodiments, the effective concentration of one or more compounds according to the invention required to enhance a GCCase concentration and/or activity level may be lower than the effective concentration for a suitable reference compound that is a pharmacological chaperone for a GCCase. By “lower” is meant a compound concentration decreased by any value between about 10% and about 90%, or of any value between about 30% and about 60%, or over about 100%, or a decrease by about 1-fold, 2-fold, 5-fold, 10-fold, 50-fold, 100-fold, or more, in comparison to the effective concentration of a reference compound that is a pharmacological chaperone for a GCCase.

[0033] In some embodiments, a pharmacological chaperone of a GCCase may inhibit the cleavage of glucose from glucosylceramide. In some embodiments, a pharmacological chaperone of a GCCase may increase protein levels of a GCCase. In some embodiments, a pharmacological chaperone of a GCCase may increase enzymatic activity levels of a GCCase. In some embodiments, a pharmacological chaperone of a GCCase may inhibit aggregation of an alpha-synuclein protein and/or inhibit formation of Lewy bodies. By “inhibit,” “inhibition” or “inhibiting” means a decrease by any value between about 10% and about 90%, or of any value between about 30% and about 60%, or over about 100%, or a decrease by about 1-fold, 2-fold, 5-fold, 10-fold or more, in comparison to a reference sample or compound, or in comparison to a wild type GCCase. It is to be understood that the inhibiting does not require full inhibition. In some embodiments, the inhibition may be transient. In some embodiments, an inhibitor or modulator, or pharmacological chaperone of a GCCase may elevate or enhance GCCase protein levels and/or enzymatic activity levels in cells, tissues, or organs (e.g., in brain, liver, spleen, or muscle tissue) and in animals.

[0034] In some embodiments, one or more of the compounds of the present invention may be useful as agents that produce a decrease in alpha-synuclein aggregation and Lewy body formation.


[0035] In some embodiments, one or more of the compounds of the present invention may elevate GCCase protein levels *in vivo* specifically via interaction with a GCCase enzyme, and may be effective in treating conditions which require or respond to enhancement of GCCase activity.

[0036] By “elevating” or “enhancing” or “increasing” is meant an increase by any value between about 5% and about 90%, or of any value between about 30% and about 60%, or over 100 about %, or an increase by about 1-fold, 2-fold, 5-fold, 10-fold, 15-fold, 25-fold, 50-fold, 100-fold or more, in comparison to a reference sample or compound, or in comparison to a wild type GCase.

[0037] In some embodiments, one or more of the compounds according to the invention may exhibit enhanced permeability. Permeability can be assessed using a variety of standard experimental techniques, including without limitation in situ perfusion, ex vivo tissue diffusion, in vitro cell monolayers (e.g. Caco-2 cells, MDCK cells, LLC-PK1 cells), and artificial cell membranes (e.g. PAMPA assay); suitable techniques for measuring effective permeability (P_{eff}) or apparent permeability (P_{app}) are reviewed for example by Volpe in *The AAPS Journal*, **2010**, 12(4), 670-678. In some embodiments, one or more of the compounds according to the invention may show enhanced permeability when tested in one or more of these assays for determining P_{eff} or P_{app} . In some embodiments, a compound that exhibits enhanced permeability may exhibit greater oral absorption. In some embodiments, a compound that exhibits enhanced permeability may exhibit greater brain penetrance when administered in vivo. In some embodiments, a compound that exhibits enhanced permeability may achieve higher brain concentrations when administered in vivo. In some embodiments, a compound that exhibits enhanced permeability may exhibit a higher brain/plasma concentration ratio when administered in vivo. In some embodiments, “enhanced permeability” means an increase in measured P_{eff} or P_{app} by any value between about 10% and about 100%, or of any integer value between about 10% and about 100%, for example, about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or over 100%, or an increase by about 1-fold, 2-fold, or 3-fold, or more, as compared to a suitable reference compound such as, for example, (3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol (isofagomine). In some embodiments, “enhanced permeability” means a measurable P_{app} value (i.e. a value greater than zero) in the assay described below for determination of P_{app} in LLC-PK1 cells. In some embodiments, “enhanced permeability” means a P_{app} value greater than 2×10^{-6} cm/s in the assay described below for determination of P_{app} in LLC-PK1 cells. In alternative embodiments, “enhanced permeability” means a P_{app} value in the range 2×10^{-6} cm/s to 40×10^{-6} cm/s in the assay described below for determination of P_{app} in LLC-PK1 cells.

[0038] By a “reference compound” or “control” is meant a carbohydrate mimetic iminosugar described in the literature that is a GCCase modulator and/or a pharmacological chaperone of a GCCase.⁹ Examples of reference compounds or controls that are GCCase modulators include, without limitation, (3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol (isofagomine), and
 5 (1S,6S,7R,8R,8aR)-octahydroindolizine-1,6,7,8-tetraol (castanospermine). Examples of reference compounds or controls that are pharmacological chaperones of a GCCase include, without limitation, (3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol (isofagomine), and (1S,6S,7R,8R,8aR)-octahydroindolizine-1,6,7,8-tetraol (castanospermine).

[0039] In some embodiments, the invention provides compounds described generally by
 10 Formula (I), including any one or more of Formula (Ia) - (If), and the salts, prodrugs, and enantiomeric forms thereof:



(I)

as set forth in Formula (I): R¹ may be OH and R² may be H or methyl; or R¹ may be F
 15 and R² may be H or F; or R¹ may be H and R² may be F; R³ may be: C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, C₃₋₈ cycloalkyl, C₄₋₁₀ cycloalkylalkyl, C₂₋₁₀ alkoxyalkyl, C₇₋₁₅ arylalkyl, or C₂₋₁₅ heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH₃, and/or OH; or R³ may be CN, CO₂H, C(O)NHCH₃, or C(O)NH(cyclopropyl); and R⁴ may be: H, C₁₋₁₀ alkyl, the C₁₋₁₀ alkyl
 20 optionally substituted from one up to the maximum number of substituents with F and/or OH.

[0040] In some embodiments, R¹ as set forth in Formula (I) may be F or OH. In some embodiments, R¹ may be OH. In some embodiments, R¹ may be F.

[0041] In some embodiments, R² as set forth in Formula (I) may be H, F, or methyl. In some
 25 embodiments, R² may be H or F. In some embodiments, R² may be methyl. In some embodiments, R² may be F. In some embodiments, R² may be H.

[0042] In some embodiments, R³ as set forth in Formula (I) may be: C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, C₃₋₈ cycloalkyl, C₄₋₁₀ cycloalkylalkyl, C₂₋₁₀ alkoxyalkyl, C₇₋₁₅

arylalkyl, or C₂₋₁₅ heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH₃, and/or OH; or R³ may be CN, CO₂H, C(O)NHCH₃, or C(O)NH(cyclopropyl). In some embodiments, R³ may be: hydroxymethyl, fluoromethyl, difluoromethyl, chloromethyl, methoxymethyl, methoxy, CN, CO₂H,

5 C(O)NHCH₃, C(O)NH(cyclopropyl), ethynyl, (S)-1-hydroxyethyl, (R)-1-hydroxyethyl, (S)-1-fluoroethyl, (R)-1-fluoroethyl, 2-hydroxypropan-2-yl, 2-fluoropropan-2-yl, 1,1-difluoroethyl, 1-fluoropropyl, (R)-2,2,2-trifluoro-1-hydroxyethyl, (S)-2,2,2-trifluoro-1-hydroxyethyl, methyl, ethyl, propyl, isopropyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, cyclopropyl, 2,2-difluorocyclopropyl, benzyl, 4-fluorobenzyl, 2-cyclohexyl-1-

10 hydroxyethyl, hydroxy(phenyl)methyl, (4-fluorophenyl)(hydroxy)methyl, (3,5-difluorophenyl)(hydroxy)methyl, hydroxy(p-tolyl)methyl, 2-cyclohexyl-1-fluoroethyl, (3,5-difluorophenyl)fluoromethyl, pyridin-3-ylmethyl, prop-1-yn-1-yl, but-1-yn-1-yl, pent-1-yn-1-yl, 3-hydroxyprop-1-yn-1-yl, 3-fluoroprop-1-yn-1-yl, 3,3-difluoroprop-1-yn-1-yl, 3,3,3-trifluoroprop-1-yn-1-yl, 4-fluorobut-1-yn-1-yl, 4,4-difluorobut-1-yn-1-yl, vinyl, prop-1-en-2-

15 yl, (E)-prop-1-en-1-yl, (Z)-prop-1-en-1-yl, (E)-but-1-en-1-yl, 1-fluorovinyl, (E)-2-fluorovinyl, (Z)-2-fluorovinyl, 2,2-difluorovinyl, 1,2,2-trifluorovinyl, and (E)-3,3,3-trifluoroprop-1-en-1-yl. In some embodiments, R³ may be: methyl, hydroxymethyl, fluoromethyl, difluoromethyl, chloromethyl, methoxymethyl, methoxy, CN, CO₂H, C(O)NHCH₃, C(O)NH(cyclopropyl), ethyl, propyl, 2-fluoroethyl, 2,2-difluoroethyl, vinyl,

20 (Z)-2-fluorovinyl, (E)-2-fluorovinyl, 2,2-difluorovinyl, ethynyl, prop-1-yn-1-yl, but-1-yn-1-yl, pent-1-yn-1-yl, 3-hydroxyprop-1-yn-1-yl, 3-fluoroprop-1-yn-1-yl, 3,3-difluoroprop-1-yn-1-yl, 4-fluorobut-1-yn-1-yl, and 4,4-difluorobut-1-yn-1-yl. In some embodiments, R³ may be methyl. In some embodiments, R³ may be ethyl. In some embodiments, R³ may be difluoromethyl. In some embodiments, R³ may be ethynyl. In some embodiments, R³ may be prop-1-yn-1-yl.

25

[0043] In some embodiments, R⁴ as set forth in Formula (I) may be: H, C₁₋₁₀ alkyl, the C₁₋₁₀ alkyl optionally substituted from one up to the maximum number of substituents with fluoro and/or OH. In some embodiments, R⁴ may be 2-fluoroethyl, butyl, 5,5,5-trifluoropentyl, 6-hydroxyhexyl, or 5-methylhexyl. In some embodiments, R⁴ may be methyl. In some

30

embodiments, R⁴ may be H.

[0044] In some embodiments, R¹ may be OH; R² may be H; R³ may be methyl, hydroxymethyl, fluoromethyl, difluoromethyl, chloromethyl, methoxymethyl, methoxy, CN, CO₂H, C(O)NHCH₃, C(O)NH(cyclopropyl), ethyl, propyl, 2-fluoroethyl, 2,2-difluoroethyl,

vinyl, (Z)-2-fluorovinyl, (E)-2-fluorovinyl, 2,2-difluorovinyl, ethynyl, prop-1-yn-1-yl, but-1-yn-1-yl, pent-1-yn-1-yl, 3-hydroxyprop-1-yn-1-yl, 3-fluoroprop-1-yn-1-yl, 3,3-difluoroprop-1-yn-1-yl, 4-fluorobut-1-yn-1-yl, or 4,4-difluorobut-1-yn-1-yl; and R⁴ may be H.

[0045] In some embodiments, R¹ may be OH; R² may be H; R³ may be methyl, ethyl, fluoromethyl, difluoromethyl, ethynyl, or prop-1-yn-1-yl; and R⁴ may be H.

[0046] In some embodiments, R¹ may be OH; R² may be H; R³ may be methyl; and R⁴ may be H.

[0047] In some embodiments, R¹ may be OH; R² may be H; R³ may be ethyl; and R⁴ may be H.





[0048] In some embodiments, R¹ may be OH; R² may be H; R³ may be difluoromethyl; and R⁴ may be H.

[0049] In some embodiments, R¹ may be OH; R² may be H; R³ may be ethynyl; and R⁴ may be H.











[0050] In some embodiments, R¹ may be OH; R² may be H; R³ may be prop-1-yn-1-yl; and R⁴ may be H.

[0051] In specific embodiments of the invention, compounds according to Formula (I) include the compounds described in Table 1.

Table 1

Example	Name	Structure
1	(6R,7R,8S)-8-methyl-4-azaspiro[2.5]octane-6,7-diol	
2	(6R,7R,8R)-8-(hydroxymethyl)-4-azaspiro[2.5]octane-6,7-diol	
3	(6R,7R,8S)-8-(fluoromethyl)-4-azaspiro[2.5]octane-6,7-diol	
4	(6R,7R,8S)-8-(difluoromethyl)-4-azaspiro[2.5]octane-6,7-diol	











Example	Name	Structure
5	(6R,7R,8S)-8-(chloromethyl)-4-azaspiro[2.5]octane-6,7-diol	
6	(6R,7R,8R)-8-(methoxymethyl)-4-azaspiro[2.5]octane-6,7-diol	
7	(6R,7S,8S)-8-methoxy-4-azaspiro[2.5]octane-6,7-diol	
8	(6R,7R,8R)-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carbonitrile	
9	(6R,7R,8S)-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carboxylic acid	
10	(6R,7R,8S)-6,7-dihydroxy-N-methyl-4-azaspiro[2.5]octane-8-carboxamide	
11	(6R,7R,8S)-N-cyclopropyl-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carboxamide	
12	(6R,7R,8S)-8-ethyl-4-azaspiro[2.5]octane-6,7-diol	
13	(6R,7R,8S)-8-propyl-4-azaspiro[2.5]octane-6,7-diol	
14	(6R,7R,8S)-8-(2-fluoroethyl)-4-azaspiro[2.5]octane-6,7-diol	

Example	Name	Structure
15	(6R,7R,8S)-8-(2,2-difluoroethyl)-4-azaspiro[2.5]octane-6,7-diol	
16	(6R,7R,8S)-8-vinyl-4-azaspiro[2.5]octane-6,7-diol	
17	(6R,7R,8S)-8-((Z)-2-fluorovinyl)-4-azaspiro[2.5]octane-6,7-diol	
18	(6R,7R,8S)-8-((E)-2-fluorovinyl)-4-azaspiro[2.5]octane-6,7-diol	
19	(6R,7R,8S)-8-(2,2-difluorovinyl)-4-azaspiro[2.5]octane-6,7-diol	
20	(6R,7R,8S)-8-ethynyl-4-azaspiro[2.5]octane-6,7-diol	
21	(6R,7R,8S)-8-(prop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol	
22	(6R,7R,8S)-8-(but-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol	
23	(6R,7R,8S)-8-(pent-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol	
24	(6R,7R,8S)-8-(3-hydroxyprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol	



Example	Name	Structure
25	(6R,7R,8S)-8-(3-fluoroprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol	
26	(6R,7R,8S)-8-(3,3-difluoroprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol	
27	(6R,7R,8S)-8-(4-fluorobut-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol	
28	(6R,7R,8S)-8-(4,4-difluorobut-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol	
29	(6R,7R,8R)-8-(hydroxymethyl)-4-methyl-4-azaspiro[2.5]octane-6,7-diol	
30	(6R,7R,8R)-8-((S)-1-hydroxyethyl)-4-azaspiro[2.5]octane-6,7-diol	
31	(6R,7R,8R)-8-((R)-1-hydroxyethyl)-4-azaspiro[2.5]octane-6,7-diol	
32	(6R,7R,8S)-8-((S)-1-fluoroethyl)-4-azaspiro[2.5]octane-6,7-diol	
33	(6R,7R,8S)-8-((R)-1-fluoroethyl)-4-azaspiro[2.5]octane-6,7-diol	
34	(6R,7R,8S)-8-(2-hydroxypropan-2-yl)-4-azaspiro[2.5]octane-6,7-diol	

Example	Name	Structure
35	(6R,7R,8S)-8-(2-fluoropropan-2-yl)-4-azaspiro[2.5]octane-6,7-diol	
36	(6R,7R,8S)-8-(1,1-difluoroethyl)-4-azaspiro[2.5]octane-6,7-diol	
37	(6R,7R,8S)-8-((R)-1-fluoropropyl)-4-azaspiro[2.5]octane-6,7-diol	
38	(6R,7R,8S)-8-((R)-2,2,2-trifluoro-1-hydroxyethyl)-4-azaspiro[2.5]octane-6,7-diol	
39	(6R,7R,8S)-8-((S)-2,2,2-trifluoro-1-hydroxyethyl)-4-azaspiro[2.5]octane-6,7-diol	
40	(6R,7R,8S)-8-isopropyl-4-azaspiro[2.5]octane-6,7-diol	
41	(6R,7R,8S)-8-(trifluoromethyl)-4-azaspiro[2.5]octane-6,7-diol	
42	(6R,7R,8S)-8-(2,2,2-trifluoroethyl)-4-azaspiro[2.5]octane-6,7-diol	
43	(6R,7R,8S)-8-cyclopropyl-4-azaspiro[2.5]octane-6,7-diol	
44	(6R,7R,8S)-8-((S)-2,2-difluorocyclopropyl)-4-azaspiro[2.5]octane-6,7-diol	


Example	Name	Structure
45	(6R,7R,8S)-8-benzyl-4-azaspiro[2.5]octane-6,7-diol	
46	(6R,7R,8S)-8-(4-fluorobenzyl)-4-azaspiro[2.5]octane-6,7-diol	
47	(6R,7R,8R)-8-((R)-2-cyclohexyl-1-hydroxyethyl)-4-azaspiro[2.5]octane-6,7-diol	
48	(6R,7R,8R)-8-((S)-hydroxy(phenyl)methyl)-4-azaspiro[2.5]octane-6,7-diol	
49	(6R,7R,8R)-8-((S)-(4-fluorophenyl)(hydroxy)methyl)-4-azaspiro[2.5]octane-6,7-diol	
50	(6R,7R,8R)-8-((S)-(3,5-difluorophenyl)(hydroxy)methyl)-4-azaspiro[2.5]octane-6,7-diol	
51	(6R,7R,8R)-8-((S)-hydroxy(p-tolyl)methyl)-4-azaspiro[2.5]octane-6,7-diol	
52	(6R,7R,8S)-8-((R)-2-cyclohexyl-1-fluoroethyl)-4-azaspiro[2.5]octane-6,7-diol	
53	(6R,7R,8S)-8-((S)-(3,5-difluorophenyl)fluoromethyl)-4-azaspiro[2.5]octane-6,7-diol	
54	(6R,7R,8R)-6-fluoro-8-(hydroxymethyl)-4-azaspiro[2.5]octan-7-ol	

Example	Name	Structure
55	(6S,7R,8R)-6-fluoro-8-(hydroxymethyl)-4-azaspiro[2.5]octan-7-ol	
56	(6R,7R,8R)-8-(hydroxymethyl)-6-methyl-4-azaspiro[2.5]octane-6,7-diol	
57	(7R,8R)-6,6-difluoro-8-(hydroxymethyl)-4-azaspiro[2.5]octan-7-ol	
58	(6R,7R,8S)-6-fluoro-8-(fluoromethyl)-4-azaspiro[2.5]octan-7-ol	
59	(6R,7R,8S)-8-(difluoromethyl)-6-fluoro-4-azaspiro[2.5]octan-7-ol	
60	(6S,7R,8S)-6-fluoro-8-(fluoromethyl)-4-azaspiro[2.5]octan-7-ol	
61	(6S,7R,8S)-8-(difluoromethyl)-6-fluoro-4-azaspiro[2.5]octan-7-ol	
62	(6R,7R,8S)-8-(pyridin-3-ylmethyl)-4-azaspiro[2.5]octane-6,7-diol	
63	(6R,7R,8S)-8-(difluoromethyl)-4-methyl-4-azaspiro[2.5]octane-6,7-diol	
64	(6R,7R,8S)-8-(difluoromethyl)-4-(2-fluoroethyl)-4-azaspiro[2.5]octane-6,7-diol	

Example	Name	Structure
65	(6R,7R,8S)-4-butyl-8-(fluoromethyl)-4-azaspiro[2.5]octane-6,7-diol	
66	(6R,7R,8S)-8-(difluoromethyl)-4-(5,5,5-trifluoropentyl)-4-azaspiro[2.5]octane-6,7-diol	
67	(6R,7R,8S)-8-(difluoromethyl)-4-(6-hydroxyhexyl)-4-azaspiro[2.5]octane-6,7-diol	
68	(6R,7R,8S)-8-(difluoromethyl)-4-(5-methylhexyl)-4-azaspiro[2.5]octane-6,7-diol	
69	(6R,7R,8S)-8-(3,3,3-trifluoroprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol	
70	(6R,7R,8S)-8-(prop-1-en-2-yl)-4-azaspiro[2.5]octane-6,7-diol	
71	(6R,7R,8S)-8-((E)-prop-1-en-1-yl)-4-azaspiro[2.5]octane-6,7-diol	
72	(6R,7R,8S)-8-((Z)-prop-1-en-1-yl)-4-azaspiro[2.5]octane-6,7-diol	
73	(6R,7R,8S)-8-((E)-but-1-en-1-yl)-4-azaspiro[2.5]octane-6,7-diol	
74	(6R,7R,8S)-8-(1-fluorovinyl)-4-azaspiro[2.5]octane-6,7-diol	

Example	Name	Structure
75	(6R,7R,8S)-8-(1,2,2-trifluorovinyl)-4-azaspiro[2.5]octane-6,7-diol	
76	(6R,7R,8S)-8-((E)-3,3,3-trifluoroprop-1-en-1-yl)-4-azaspiro[2.5]octane-6,7-diol	

[0052] As will be appreciated by a person skilled in the art, Formula (I) above may also be represented alternatively as follows:



5 as used herein the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. For example, “a compound” refers to one or more of such compounds, while “the enzyme” includes a particular enzyme as well as other family member equivalents thereof as known to those skilled in the art.

[0053] Throughout this application, it is contemplated that the term “compound” or
 10 “compounds” refers to the compounds discussed herein and includes precursors and derivatives of the compounds, including acyl-protected derivatives, and pharmaceutically acceptable salts of the compounds, precursors, and derivatives. The invention also includes prodrugs of the compounds, pharmaceutical compositions including the compounds and a pharmaceutically acceptable carrier, and pharmaceutical compositions including prodrugs of
 15 the compounds and a pharmaceutically acceptable carrier.

[0054] The compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such
 20 asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified

compounds are included within the ambit of this invention. Any formulas, structures or names of compounds described in this specification that do not specify a particular stereochemistry are meant to encompass any and all existing isomers as described above and mixtures thereof in any proportion. When stereochemistry is specified, the invention is
5 meant to encompass that particular isomer in pure form or as part of a mixture with other isomers in any proportion.

[0055] "Alkyl" refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing no unsaturation and including, for example, from one to ten carbon atoms, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, and which is attached
10 to the rest of the molecule by a single bond. In alternative embodiments, the alkyl group may contain from one to eight carbon atoms, such as 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms. In alternative embodiments, the alkyl group may contain from one to six carbon atoms, such as 1, 2, 3, 4, 5, or 6 carbon atoms. Unless stated otherwise specifically in the specification, the alkyl group may be optionally substituted by one or more substituents as described herein.

15 Unless stated otherwise specifically herein, it is understood that the substitution can occur on any carbon of the alkyl group.

[0056] "Alkenyl" refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing at least one double bond and including, for example, from two to ten carbon atoms, such as 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, and
20 which is attached to the rest of the molecule by a single bond. In alternative embodiments, the alkenyl group may contain from two to eight carbon atoms, such as 2, 3, 4, 5, 6, 7, or 8 carbon atoms. In alternative embodiments, the alkenyl group may contain from three to six carbon atoms, such as 3, 4, 5, or 6 carbon atoms. Unless stated otherwise specifically in the specification, the alkenyl group may be optionally substituted by one or more substituents as
25 described herein. Unless stated otherwise specifically herein, it is understood that the substitution can occur on any carbon of the alkenyl group.

[0057] "Alkynyl" refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing at least one triple bond and including, for example, from two to ten carbon atoms, such as 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, and which is
30 attached to the rest of the molecule by a single bond. In alternative embodiments, the alkynyl group may contain from two to eight carbon atoms, such as 2, 3, 4, 5, 6, 7, or 8 carbon atoms. In alternative embodiments, the alkynyl group may contain from three to six carbon atoms, such as 3, 4, 5, or 6 carbon atoms. Unless stated otherwise specifically in the specification,

the alkynyl group may be optionally substituted by one or more substituents as described herein.

[0058] "Aryl" refers to a mono- or bicyclic aromatic ring containing only carbon atoms, including for example, 6-14 members, such as 6, 7, 8, 9, 10, 11, 12, 13, or 14 members.

5 Examples of aryl groups include phenyl, biphenyl, naphthyl, indanyl, indenyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, 1,4-benzodioxanyl, and the like. Unless stated otherwise specifically herein, the term "aryl" is meant to include aryl groups optionally substituted by one or more substituents as described herein.

[0059] "Heteroaryl" refers to a single or fused aromatic ring group containing one or more
10 heteroatoms in the ring, for example N, O, S, including for example, 5-14 members, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 members. Examples of heteroaryl groups include furan, thiophene, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, 1,2,3-oxadiazole, 1,2,3-triazole, 1,2,4-triazole, 1,3,4-thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,3,5-triazine, imidazole, benzimidazole, benzoxazole, benzothiazole,
15 indolizine, indole, isoindole, benzofuran, benzothiophene, 1H-indazole, purine, 4H-quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, pteridine, and the like. Unless stated otherwise specifically herein, the term "heteroaryl" is meant to include heteroaryl groups optionally substituted by one or more substituents as described herein.

[0060] "Arylalkyl" refers to a group of the formula $-R_aR_b$ where R_a is a C_{1-10} alkyl group as
20 described herein and R_b is one or more aryl moieties as described herein. The arylalkyl group(s) may be optionally substituted as described herein.

[0061] "Heteroarylalkyl" refers to a group of the formula $-R_aR_c$ where R_a is a C_{1-10} alkyl
25 group as described herein and R_c is one or more heteroaryl moieties as described herein. The heteroarylalkyl group(s) may be optionally substituted as described herein.

[0062] "Alkoxyalkyl" refers to a group of the formula $-R_aOR_a$, where each R_a is independently a C_{1-10} alkyl or a C_{1-6} alkyl or a C_{1-5} alkyl group as described herein. The alkoxyalkyl group(s) may be optionally substituted as described herein.

[0063] "Alkoxy" refers to a group of the formula $-OR_a$, where each R_a is independently a C_{1-10}
30 alkyl or a C_{1-6} alkyl or a C_{1-5} alkyl group as described herein. The alkoxy group(s) may be optionally substituted as described herein.

[0064] “Cycloalkyl” refers to a stable monovalent monocyclic, bicyclic or tricyclic hydrocarbon group consisting solely of carbon and hydrogen atoms, having for example from 3 to 15 carbon atoms, and which is saturated and attached to the rest of the molecule by a single bond. In alternative embodiments, the cycloalkyl group may contain from three to six carbon atoms, such as 3, 4, 5, or 6 carbon atoms. Unless otherwise stated specifically herein, the term “cycloalkyl” is meant to include cycloalkyl groups which are optionally substituted as described herein.

[0065] “Cycloalkylalkyl” refers to a group of the formula $-R_aR_d$, where R_a is a C_{1-10} alkyl or a C_{1-6} alkyl group as described herein and R_d is a C_{3-8} cycloalkyl group as described herein.

The cycloalkylalkyl group(s) may be optionally substituted as described herein.

[0066] “Cycloalkylmethyl” refers to a group of the formula $-CH_2R_d$, where R_d is a C_{3-8} cycloalkyl group as described herein. The cycloalkylmethyl group(s) may be optionally substituted as described herein.

[0067] “Halo” refers to bromo, chloro, fluoro, iodo, etc. In some embodiments, suitable halogens include fluorine or chlorine.

[0068] “Optional” or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where the event or circumstance occurs one or more times and instances in which it does not. For example, “optionally substituted alkyl” means that the alkyl group may or may not be substituted and that the description includes both substituted alkyl groups and alkyl groups having no substitution, and that the alkyl groups may be substituted one or more times.

Examples of optionally substituted alkyl groups include, without limitation, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, etc. Examples of suitable optional substituents include, without limitation, H, F, Cl, CH_3 , OH, OCH_3 , CF_3 , CHF_2 , CH_2F , CN, halo, and C_{1-10} alkoxy.

Therapeutic Indications

[0069] The invention provides, in part, methods of treating conditions that are modulated, directly or indirectly, by a GCCase enzyme or by GCCase protein levels or GCCase activity levels, for example, a condition that is benefited by modulating a GCCase enzyme or by an elevation of GCCase protein levels or by an elevation of GCCase enzyme activity levels. Such conditions may include, without limitation, neurodegenerative diseases, such as Parkinson’s

disease (PD), synucleopathies, and lysosomal storage diseases, such as Gaucher's disease. Thus, one or more of the compounds of the invention may be used to treat a subject at risk for developing, or already diagnosed with, various neurodegenerative or other diseases. In alternative embodiments, one or more of the compounds of the invention may be used to treat a subject carrying a chaperone-responsive GCCase mutation. The term "treating" as used herein includes treatment, prevention, and amelioration.

[0070] In alternative embodiments, one or more of the compounds of the invention may also be useful in the treatment of diseases or disorders related to deficiency or over-expression of GCCase or accumulation or depletion of glucosylceramide, or any disease or disorder responsive to glycosidase modulator therapy, glycosidase inhibition therapy or glycosidase pharmacological chaperone therapy. Such diseases and disorders may include, but are not limited to, neurodegenerative diseases, such as Parkinson's disease (PD), synucleopathies, and lysosomal storage diseases, such as Gaucher's disease. Such diseases and disorders may also include diseases or disorders related to the accumulation or deficiency in the enzyme glucosylceramide synthase. Also included is a method of protecting or treating target cells expressing GCCase, the dysregulation of which may result in disease or pathology.

[0071] In alternative embodiments, the invention provides methods of enhancing or elevating levels of GCCase protein and/or GCCase enzyme activity levels in animal subjects, such as, veterinary and human subjects. This elevation of GCCase protein and/or activity levels may be useful for the prevention or treatment of Parkinson's disease; prevention or treatment of other neurodegenerative diseases (*e.g.* Alzheimer's disease, Pick's disease); providing neuroprotective effects; preventing damage to dopaminergic neurons; and treating diseases associated with genetic deficiency of GCCase, such as Gaucher's disease.

[0072] In alternative embodiments, the invention provides methods of inhibiting and/or modulating a GCCase enzyme in animal subjects, such as veterinary and human subjects.

[0073] In alternative embodiments, the invention provides methods of chaperoning a GCCase enzyme in animal subjects, such as, veterinary and human subjects.

[0074] In alternative embodiments, the invention provides methods of inhibiting aggregation of alpha-synuclein protein, or inhibiting formation of Lewy bodies, in animal subjects, such as, veterinary and human subjects. Disease states of interest may include Parkinson's disease (PD) and related neurodegenerative synucleopathies, in which abnormal aggregation of the alpha-synuclein protein is involved in disease pathogenesis. In some embodiments, a

compound according to the invention may be used to block aggregation of alpha-synuclein protein by maintaining elevated protein levels of GCcase and/or elevated GCcase enzyme activity levels, thereby providing therapeutic benefit.

[0075] Neurodegenerative diseases that may be treated with a compound of the invention include, without limitation: Parkinson's disease, Dementia with Lewy bodies, Multiple system atrophy, Pick's disease (PiD), Corticobasal degeneration (CBD), Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Amyotrophic lateral sclerosis with cognitive impairment (ALSci), Argyrophilic grain dementia, Bluit disease, Dementia pugilistica, Diffuse neurofibrillary tangles with calcification, Down's syndrome, Familial British dementia, Familial Danish dementia, Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Gerstmann-Straussler-Scheinker disease, Guadeloupean parkinsonism, Hallevorden-Spatz disease (neurodegeneration with brain iron accumulation type 1), Myotonic dystrophy, Multi-infarct dementia, Niemann-Pick disease (type C), Pallido-ponto-nigral degeneration, Parkinsonism-dementia complex of Guam, Post-encephalitic parkinsonism (PEP), Prion diseases (including Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (vCJD), Fatal Familial Insomnia, and Kuru), Progressive supracortical gliosis, Progressive supranuclear palsy (PSP), Richardson's syndrome, Subacute sclerosing panencephalitis, Tangle-only dementia, Huntington's disease, Schizophrenia, Mild Cognitive Impairment (MCI), Neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, and diabetic neuropathy), or Glaucoma.

[0076] Lysosomal storage diseases that may be treated with a compound of the invention may include, without limitation: Gaucher's disease, including Type I (non-neuronopathic), Type II (acute infantile neuronopathic), and Type III (chronic neuronopathic) Gaucher's disease.

[0077] In some embodiments, a compound according to the invention may be useful in the treatment of a disorder in which the regulation of GCcase protein levels and/or enzyme activity levels are implicated, or any condition as described herein.

[0078] Other conditions that may be treated using one or more of the compounds according to the invention are those triggered, affected, or in any other way correlated with levels of GCcase protein or GCcase enzyme activity. It is expected that one or more of the compounds of this invention may be useful for the treatment of such conditions and in particular, but not limited to, Parkinson's disease and Gaucher's disease.

Pharmaceutical & Veterinary Compositions, Dosages, And Administration

[0079] Pharmaceutical compositions including compounds according to the invention, or for use according to the invention, are contemplated as being within the scope of the invention.

In some embodiments, pharmaceutical compositions including an effective amount of a compound of Formula (I), including any one or more of Formula (Ia) - (If), are provided.

[0080] The compounds of Formula (I), including any one or more of Formula (Ia) - (If), and their pharmaceutically acceptable salts, enantiomers, solvates, and derivatives may be useful because they may have pharmacological activity in animals, including humans. In some embodiments, one or more of the compounds according to the invention may be stable in plasma, when administered to a subject, such as a human.

[0081] In general, a compound according to the invention may be administered to a subject in need thereof, or by contacting a cell or a sample, for example, a pharmaceutical composition comprising a therapeutically effective amount of the compound according to Formula (I), including any one or more of Formula (Ia) - (If).

[0082] In some embodiments, a compound according to the invention, or for use according to the invention, may be provided in combination with any other active agents or pharmaceutical compositions where such combined therapy may be useful to modulate GCCase protein and/or activity levels, for example, to treat neurodegenerative, or lysosomal storage diseases, or any condition described herein. In some embodiments, a compound according to the invention, or for use according to the invention, may be provided in combination with one or more agents useful in the prevention or treatment of Parkinson's disease. Examples of such agents may include, without limitation,

- Levodopa (L-DOPA);
- A peripheral DOPA decarboxylase inhibitor (DDCI), such as Carbidopa (Lodosyn®);
- Combined carbidopa/levodopa (Kinson®, Sinemet®, Parcopa®, Atamet®);
- Combined carbidopa/levodopa/entacapone (Stalevo®);
- Amantadine (Symmetrel®);
- Dopamine antagonists, such as bromocriptine (Cycloset®, Parlodel®), pergolide (Permax®), pramipexole (Mirapexin®, Sifrol®, Mirapex®), ropinirole (Ronirole®, Adartrel®, Requip®), piribedil (Trivastal Retard®, Trastal®, Trivastan®, Clarium®, Pronoran®), cabergoline (Cabaser®, Dostinex®), apomorphine (Ixense®, Spontane®, Uprima®, Apokyn®), Lisuride® (Dopergin®, Proclacam®, Revanil®),

- rotigotine (Neupro®), Ciladopa® (AY-27,110), Dihydropyridine® (DAR-0100), Dinapsoline®, Doxanthrine®, epicriptine (beta-dihydroergocryptine), N-n-propylnorapomorphine (NPA), quinagolide (Norprolac®), Roxindole® (EMD-49,980), Sumanitrole® (PNU-95,666), pardoprunox, aplindore, etc.;
- 5 • Monoamine oxidase-B (MAO-B) inhibitors, such as selegiline (Anipryl®, L-deprenyl®, Eldepryl®, Emsam®, Zelapar®) rasagiline (Azilect®, AGN 1135), safinamide, etc.;
- Anticholinergics, such as benztropine (benztropine, Cogentin®), diphenhydramine (Benadryl®, Dimedrol®, Daedalon®, Nytol®), orphenadrine (Norflex®,
- 10 Mephenamin®, Disipal®, Banflex®, Flexon®, Biorphen®, Brocasipal®, Dolan®, Norgesic®, OrfenAce®), trihexyphenidyl (Artane®, Apo-Trihex®, Parkin®, Pacitane®, benzhexol, trihex), etc.;
- Catechol-O-methyl transferase (COMT) inhibitors, such as entacapone (COMTan®), tolcapone (Tasmar®), nitecapone, nebicapone, etc.;
- 15 • Adenosine A_{2A} receptor antagonists, such as istradefylline (KW-6002), preladenant, fipamezole (JP-1730), SCH-420814, BIIA-014, Lu AA4707, etc.;
- Metabotropic glutamate receptor 5 (mgluR5) modulators, such as dipraglurant, etc.;
- AMPA receptor antagonists, such as perampanel (Fycompa®), etc.;
- Anticonvulsants, such as zonisamide (Tremode®), etc.;
- 20 • Nicotinic acetylcholine receptor (nAChR) agonists, such as nicotine, ABT-418, WAY-317,538 (SEN-12333), EVP-6124, MEM 3454, Nefiracetam, etc.
- Acetylcholine esterase inhibitors (AChEIs) such as Aricept® (Donepezil), Exelon® (Rivastigmine), Razadyne® (Razadyne ER®, Reminyl®, Nivalin®, galantamine), Cognex® (Tacrine), Huperzine A, Phenserine, Debio-9902 SR (ZT-1 SR), Zanapezil
- 25 (TAK0147), ganstigmine, NP7557, etc.;
- Atypical antipsychotics, such as clozapine, etc.; and
- Modafinil (Alertec®, Modavigil®, Provigil®).

[0083] It is to be understood that combination of compounds according to the invention, or for use according to the invention, with Parkinson's agents is not limited to the examples

30 described herein, but may include combination with any agent useful for the treatment of Parkinson's disease. Combination of compounds according to the invention, or for use according to the invention, and other Parkinson's agents may be administered separately or in

conjunction. The administration of one agent may be prior to, concurrent to, or subsequent to the administration of other agent(s).

[0084] In some embodiments, a compound according to the invention, or for use according to the invention, may be provided in combination with one or more agents useful in the prevention or treatment of Gaucher's disease. Examples of such agents may include, without limitation,

- Recombinant human GCCase enzyme replacement therapy, such as imiglucerase (Cerezyme®), velaglucerase alfa (VPRIV®), taliglucerase alfa (Elelyso®), etc.;
- Glucosylceramide synthase inhibitors, such as *N*-butyl-deoxynojirimycin (Zavesca®), miglustat, EXEL-0346, Genz-123346, Eliglustat® (Genz-112638), etc.;
- Bisphosphonates, such as zoledronate (Zometa®, Zomera®, Aclasta®, Reclast®), alendronate sodium (Fosamax®), etidronate (Didronel®), clodronate (Bonefos®, Loron®), tiludronate (Skelid®), pamidronate (APD®, Aredia®), neridronate (Nerixia®), olpadronate, ibandronate (Boniva®), risedronate (Actonel®), etc.;
- Antiepileptics, such as Tegretol® (Carbatrol®, carbamazepine), Zarontin® (ethosuximide), Felbatol® (felbamate), Gabitril® (tiagabine), Keppra® (levetiracetam), Lamictal® (lamotrigine), Lyrica® (pregabalin), Neurontin® (gabapentin), Dilantin® (phenytoin), Topamax® (topiramate), Trileptal® (oxcarbazepine), Depakene® (Depakote®, valproate, valproic acid), Zonegran® (zonisamide), Valium® (diazepam), Ativan® (lorazepam) Klonopin® (clonazepam), Fycompa® (perampanel), Oxtellar XR® (oxcarbazepine), etc.; and
- Gene therapy.

[0085] It is to be understood that combination of compounds according to the invention, or for use according to the invention, with Gaucher's agents is not limited to the examples described herein, but may include combination with any agent useful for the treatment of Gaucher's disease. Combination of compounds according to the invention, or for use according to the invention, and other Gaucher's agents may be administered separately or in conjunction. The administration of one agent may be prior to, concurrent to, or subsequent to the administration of other agent(s).

[0086] In alternative embodiments, a compound may be supplied as a "prodrug" or protected forms, which release the compound after administration to a subject. For example, a compound may carry a protective group which is split off by hydrolysis in body fluids, *e.g.*,

in the bloodstream, thus releasing the active compound or is oxidized or reduced in body fluids to release the compound. Accordingly, a “prodrug” is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention. Thus, the term “prodrug” refers to a metabolic precursor of a compound of the invention that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject in need thereof, but may be converted *in vivo* to an active compound of the invention. Prodrugs are typically rapidly transformed *in vivo* to yield the parent compound of the invention, for example, by hydrolysis in blood. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a subject.

5 [0087] The term “prodrug” is also meant to include any covalently bonded carriers which release the active compound of the invention *in vivo* when such prodrug is administered to a subject. Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compound of the invention.

15 Prodrugs include compounds of the invention where a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and acetamide, formamide, and benzamide derivatives of amine functional groups in one or more of the compounds of the invention and the like.

20 [0088] A discussion of prodrugs may be found in “Smith and Williams’ Introduction to the Principles of Drug Design,” H.J. Smith, Wright, Second Edition, London (1988); Bundgaard, H., *Design of Prodrugs* (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam); The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch 31, (Academic Press, 1996); A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch 5, pgs 113 191 (Harwood Academic Publishers, 1991); Higuchi, T., *et al.*, “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series, Vol. 14; or in *Bioreversible Carriers in Drug Design*, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

25 [0089] Suitable prodrug forms of one or more of the compounds of the invention may include embodiments in which one or more OH groups as set forth in Formula (I), including any one or more of Formula (Ia) - (If), may be protected as OC(O)R, where R may be optionally substituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl. In these cases the ester groups may be

hydrolyzed in vivo (e.g. in bodily fluids), liberating the OH groups and releasing the active compounds. Preferred prodrug embodiments of the invention may include compounds of Formula (I), including any one or more of Formula (Ia) - (If), where one or more OH groups may be protected with acetate, for example as OC(O)CH₃.

5 [0090] Compounds according to the invention, or for use according to the invention, may be provided alone or in combination with other compounds in the presence of a liposome, an adjuvant, or any pharmaceutically acceptable carrier, diluent or excipient, in a form suitable for administration to a subject such as a mammal, for example, humans, cattle, sheep, etc. If desired, treatment with a compound according to the invention may be combined with more
10 traditional and existing therapies for the therapeutic indications described herein. Compounds according to the invention may be provided chronically or intermittently. “Chronic” administration refers to administration of the compound(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. “Intermittent” administration is treatment that is not consecutively
15 done without interruption, but rather is cyclic in nature. The terms “administration,” “administrable,” or “administering” as used herein should be understood to mean providing a compound of the invention to the subject in need of treatment.

[0091] “Pharmaceutically acceptable carrier, diluent or excipient” may include, without
20 limitation, any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier that has been approved, for example, by the United States Food and Drug Administration or other governmental agency as being acceptable for use in humans or domestic animals.

[0092] A compound of the present invention may be administered in the form of a
25 pharmaceutically acceptable salt. In such cases, pharmaceutical compositions in accordance with this invention may comprise a salt of such a compound, preferably a physiologically acceptable salt, which are known in the art. In some embodiments, the term “pharmaceutically acceptable salt” as used herein means an active ingredient comprising compounds of Formula I used in the form of a salt thereof, particularly where the salt form
30 confers on the active ingredient improved pharmacokinetic properties as compared to the free form of the active ingredient or other previously disclosed salt form.

[0093] A “pharmaceutically acceptable salt” may include both acid and base addition salts. A “pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which may be formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.

10 [0094] A “pharmaceutically acceptable base addition salt” refers to those salts which may retain the biological effectiveness and properties of the free acids, which may not be biologically or otherwise undesirable. These salts may be prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases may include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, 15 magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts may be the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases may include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, 20 diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases may be isopropylamine, diethylamine, 25 ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.

[0095] Thus, the term “pharmaceutically acceptable salt” encompasses all acceptable salts including but not limited to acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methylbromide, bromide, methylnitrite, calcium edetate, methylsulfate, camsylate, mucate, carbonate, 30 napsylate, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, phosphate/diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutame, stearate, glycolylarsanilate, sulfate, hexylresorcinat,

subacetate, hydradamine, succinate, hydrobromide, tannate, hydrochloride, tartrate, hydroxynaphthoate, teoate, iodide, tosylate, isothionate, triethiodide, lactate, panoate, valerate, and the like.

[0096] Pharmaceutically acceptable salts of a compound of the present invention may be used as a dosage for modifying solubility or hydrolysis characteristics, or may be used in sustained release or prodrug formulations. Also, pharmaceutically acceptable salts of a compound of this invention may include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethyl-amine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.

[0097] Pharmaceutical formulations may typically include one or more carriers acceptable for the mode of administration of the preparation, be it by injection, inhalation, topical administration, lavage, or other modes suitable for the selected treatment. Suitable carriers may be those known in the art for use in such modes of administration.

[0098] Suitable pharmaceutical compositions may be formulated by means known in the art and their mode of administration and dose determined by the skilled practitioner. For parenteral administration, a compound may be dissolved in sterile water or saline or a pharmaceutically acceptable vehicle used for administration of non-water soluble compounds such as those used for vitamin K. For enteral administration, the compound may be administered in a tablet, capsule or dissolved in liquid form. The table or capsule may be enteric coated, or in a formulation for sustained release. Many suitable formulations are known, including, polymeric or protein microparticles encapsulating a compound to be released, ointments, gels, hydrogels, or solutions which can be used topically or locally to administer a compound. A sustained release patch or implant may be employed to provide release over a prolonged period of time. Many techniques known to skilled practitioners are described in *Remington: the Science & Practice of Pharmacy* by Alfonso Gennaro, 20th ed., Williams & Wilkins, (2000). Formulations for parenteral administration may, for example, contain excipients, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of a compound. Other potentially useful parenteral delivery systems for

modulatory compounds may include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

[0099] A compound or a pharmaceutical composition according to the present invention may be administered by oral or non-oral, e.g., intramuscular, intraperitoneal, intravenous, intracisternal injection or infusion, subcutaneous injection, transdermal or transmucosal routes. In some embodiments, a compound or pharmaceutical composition in accordance with this invention or for use in this invention may be administered by means of a medical device or appliance such as an implant, graft, prosthesis, stent, etc. Implants may be devised which are intended to contain and release such compounds or compositions. An example would be an implant made of a polymeric material adapted to release the compound over a period of time. A compound may be administered alone or as a mixture with a pharmaceutically acceptable carrier *e.g.*, as solid formulations such as tablets, capsules, granules, powders, etc.; liquid formulations such as syrups, injections, etc.; injections, drops, suppositories, pessaryies. In some embodiments, compounds or pharmaceutical compositions in accordance with this invention or for use in this invention may be administered by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.

[00100] A compound of the invention may be used to treat animals, including mice, rats, horses, cattle, sheep, dogs, cats, and monkeys. However, a compound of the invention may also be used in other organisms, such as avian species (*e.g.*, chickens). One or more of the compounds of the invention may also be effective for use in humans. The term “subject” or alternatively referred to herein as “patient” is intended to be referred to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. However, one or more of the compounds, methods and pharmaceutical compositions of the present invention may be used in the treatment of animals. Accordingly, as used herein, a “subject” may be a human, non-human primate, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc. The subject may be suspected of having or at risk for having a condition that may require modulation of GCase activity.

[00101] An “effective amount” of a compound according to the invention may include a therapeutically effective amount or a prophylactically effective amount. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as inhibition and/or modulating of a GCCase, elevation of GCCase protein and/or enzyme activity levels, inhibition of alpha-synuclein aggregation, or any condition described herein. A therapeutically effective amount of a compound may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual.

Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount may also be one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount” may refer to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as inhibition and/or modulating of a GCCase, elevation of GCCase protein and/or enzyme activity levels, inhibition of alpha-synuclein aggregation, or any condition described herein. Typically, a prophylactic dose may be used in subjects prior to or at an earlier stage of disease, so that a prophylactically effective amount may be less than a therapeutically effective amount. A suitable range for therapeutically or prophylactically effective amounts of a compound may be any integer from 0.1 nM - 0.1 M, 0.1 nM - 0.05 M, 0.05 nM - 15 μM or 0.01 nM - 10 μM.

[00102] In alternative embodiments, in the treatment or prevention of conditions which may require modulation of GCCase activity, an appropriate dosage level may generally be about 0.01 to 500 mg per kg subject body weight per day, and may be administered in single or multiple doses. In some embodiments, the dosage level may be about 0.1 to about 250 mg/kg per day. It will be understood that the specific dose level and frequency of dosage for any particular patient may be varied and may depend upon a variety of factors including the activity of the specific compound used, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the patient undergoing therapy.

[00103] It is to be noted that dosage values may vary with the severity of the condition to be alleviated. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions. Dosage ranges set forth herein are

exemplary only and do not limit the dosage ranges that may be selected by medical practitioners. The amount of active compound(s) in the composition may vary according to factors such as the disease state, age, sex, and weight of the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It may be advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. In general, compounds of the invention should be used without causing substantial toxicity, and as described herein, one or more of the compounds may exhibit a suitable safety profile for therapeutic use. Toxicity of a compound of the invention may be determined using standard techniques, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e., the ratio between the LD50 (the dose lethal to 50% of the population) and the LD100 (the dose lethal to 100% of the population). In some circumstances however, such as in severe disease conditions, it may be necessary to administer substantial excesses of the compositions.

[00104] In the compounds of generic Formula (I), including any one or more of Formula (Ia) - (If), the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula (I), including any one or more of Formula (Ia) - (If). For example, different isotopic forms of hydrogen (H) include protium (^1H), deuterium (^2H) and tritium (^3H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing *in vivo* half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic Formula (I), including any one or more of Formula (Ia) - (If), may be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.

Other Uses

[00105] In alternative embodiments, one or more of the compounds of the invention may be used in studying the physiological role of GCCase at the cellular and organismal level. In some embodiments, one or more of the compounds may be useful in the development of animal models for studying diseases or disorders that may be related to deficiencies in GCCase, over-expression of GCCase, accumulation of glucosylceramide, depletion of glucosylceramide, and for studying treatment of diseases and disorders that may be related to deficiency or over-expression of GCCase, or accumulation or depletion of glucosylceramide. Such diseases and disorders may include neurodegenerative diseases, including Parkinson's disease, and lysosomal storage diseases, including Gaucher's disease.

[00106] The effectiveness of a compound in treating pathology associated with the accumulation of toxic alpha-synuclein species (for example, Parkinson's disease and other synucleopathies) may be confirmed by testing the ability of a compound to block the formation of toxic alpha-synuclein species in established cellular¹² and/or transgenic animal models of disease.¹³

[00107] The effectiveness of a compound in treating pathology associated with a genetic deficiency of GCCase (for example, Gaucher's disease) may be confirmed by testing the ability of a compound to increase levels of GCCase protein and/or GCCase enzyme activity in fibroblasts derived from Gaucher patients,¹⁴ or in established cellular¹⁵ and/or transgenic animal models of disease.^{14,16} Gaucher fibroblast cell lines homozygous for loss of function *GBA1* mutations may be obtained from, for example, the Coriell Institute for Medical Research.

[00108] Various alternative embodiments and examples of the invention are described herein. These embodiments and examples are illustrative and should not be construed as limiting the scope of the invention.

EXAMPLES

[00109] The following examples are intended to illustrate embodiments of the invention and are not intended to be construed in a limiting manner.

Abbreviations


AIBN = azobisisobutyronitrile

- 9-BBN = 9-borabicyclo[3.3.1]nonane
- Boc₂O = di-*tert*-butyl dicarbonate
- CAN = ceric ammonium nitrate
- DAST = diethylaminosulfur trifluoride
- 5 DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene
- DCM = dichloromethane
- DIAD = diisopropyl azodicarboxylate
- DIBAL-H = diisobutylaluminium hydride
- DIPEA = diisopropylethylamine
- 10 DMF = *N,N*-dimethylformamide
- DMP = Dess-Martin periodinane
- Et₂O = diethyl ether
- HATU = (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate)
- 15 HOBt = hydroxybenzotriazole
- MsCl = methanesulfonyl chloride
- TFA = 2,2,2-trifluoroacetic acid
- TFAA = trifluoroacetic acid anhydride
- Tf₂O = trifluoromethanesulfonic anhydride
- 20 THF = tetrahydrofuran
- thio-CDI = 1,1'-thiocarbonyldiimidazole
- TMSCF₃ = trifluoromethyltrimethylsilane
- TsOH = *p*-toluenesulfonic acid


General Procedures and Intermediates

- 25 [00110] The compounds of the invention are synthesized according to standard schemes and procedures, as indicated in, for example, Schemes 1 to 18, as appropriate. Intermediate A (Scheme 1) may be prepared as described in, for example, Example 2.


Scheme 1




Scheme 2




Scheme 3




Scheme 4




Scheme 5




Scheme 6




Scheme 7




Scheme 8




Scheme 9




Scheme 10




Scheme 11






Scheme 12




Scheme 13







Scheme 17



Scheme 18



(3R,4R,5R)-5-(hydroxymethyl)-6,6-dimethylpiperidine-3,4-diol



5

[00111] Cerium(III) chloride heptahydrate (3.34 g, 8.8 mmol) powder was stirred under vacuum at 145° C for 5 h, then at 110° C for 18 h. The solid was allowed to cool to room temperature. THF (10 mL) was added and the solid was stirred at room temperature for 2 h. The suspension was cooled to -78° C. MeLi (5 mL, 1.6 M in Et₂O, 8.0 mmol) was added dropwise. The reaction mixture was stirred -78° C for 30 min. A solution of (2S,3S,4aS,5S,8R,8aR)-5-(benzyloxy)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-pyrano[3,4-b][1,4]dioxine-8-carbonitrile (740 mg, 2.0 mmol) in THF (5 mL) was introduced

dropwise. The reaction was allowed to proceed at -78°C for 2 h, then 0°C for another 2 h. Conc. NH_4OH (5 mL) was added and the reaction mixture was allowed to warm to room temperature. DCM (50 mL) was added and the mixture was stirred at room temperature for 1 h, then filtered through a celite pad. The celite pad was washed with DCM. The combined
 5 filtrates were concentrated under reduced pressure. The obtained residue was purified by chromatography to give 2-((2S,3S,4aS,5S,8R,8aR)-5-(benzyloxy)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-pyrano[3,4-b][1,4]dioxin-8-yl)propan-2-amine (780 mg, 95%) as a light yellow oil. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.46-7.42 (m, 2H), 7.39-7.34 (m, 2H), 7.32-7.27 (m, 1H), 4.90 (d, $J = 9.6$ Hz, 1H), 4.78-4.62 (m, 2H), 4.57-4.50 (m, 1H), 4.42-4.35 (m,
 10 1H), 3.96-9.90 (m, 1H), 3.78 (dd, $J = 0.8, 12.8$ Hz, 1H), 3.285 (s, 3H), 3.236 (s, 3H), 1.90-1.85 (m, 1H), 1.40 (s, 3H), 1.35 (s, 3H), 1.31 (s, 3H), 1.23 (s, 3H); MS, (ES, m/z) $[\text{M}+\text{Na}]^+$ 396.23.


[00112] To a solution of the above material (780 mg, 1.97 mmol) in MeOH (40 mL) was added $\text{Pd}(\text{OH})_2/\text{C}$ (20 wt.%, 70 mg, 0.1 mmol) and the mixture was treated with hydrogen (1
 15 atm) for 18 h. Catalyst was filtered off through celite and the solvent was evaporated under reduced pressure to give((2S,3S,4aR,8R,8aR)-2,3-dimethoxy-2,3,7,7-tetramethyloctahydro-[1,4]dioxino[2,3-c]pyridin-8-yl)methanol as a light yellow oil (570 mg, 100%). MS, (ES, m/z) $[\text{M}+\text{Na}]^+$ 290.19.

[00113] TFA (2 mL) and H_2O (0.2 mL) mixture was cooled to 0°C , added to the above
 20 material (40 mg, 0.14 mmol) at 0°C . The mixture was stirred at 0°C for 10 min, then room temperature for 4 h. TFA was removed under vacuum. The residue was purified by silica gel flash chromatography (using 70:20:2 DCM/MeOH/ NH_4OH as eluent) to give (3R,4R,5R)-5-(hydroxymethyl)-6,6-dimethylpiperidine-3,4-diol (24 mg, 98%). $^1\text{H NMR}$ (400 MHz, CD_3OD) δ 3.92-3.82 (m, 2H), 3.69-3.60 (m, 2H), 3.31-3.25 (m, 1H), 3.02-2.92 (m, 1H), 1.68-
 25 1.60 (m, 1H), 1.53 (s, 3H), 1.41 (s, 3H); MS, (ES, m/z) $[\text{M}+\text{H}]^+$ 176.13.

Examples

Example 1

(6R,7R,8S)-8-methyl-4-azaspiro[2.5]octane-6,7-diol




30

[00114] To a solution of (2S,3S,4aR,8R,8aR)-tert-butyl 8-(hydroxymethyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (110 mg, 0.28 mmol) in THF (4 mL) at 0°C was added NaH (57%-63% in mineral oil, 50 mg, 1.25 mmol) followed by CS₂ (0.07 mL, 1.2 mmol). The mixture was stirred for 1 h at room temperature then MeI (0.15 mL, 8.6 mmol) was added dropwise. The resulting mixture was stirred for an additional 1 h, then concentrated and diluted with EtOAc. The organic phase was washed with satd. aqueous NaHCO₃ and brine then dried over MgSO₄. Evaporation of solvent gave the crude material which was purified by silica gel flash chromatography, eluting with 30% EtOAc in hexanes to afford (2S,3S,4aR,8R,8aR)-tert-butyl 2,3-dimethoxy-2,3-dimethyl-8-(((methylthio)carbonothioyl)oxy)methyl)tetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (135 mg, 100%) as a white foam.

[00115] To a refluxing solution of the above material (136 mg, 0.28 mmol) in benzene (2 mL) was added dropwise a solution of *n*-Bu₃SnH (0.11 mL, 0.42 mmol) and ABCN (7 mg, 0.028 mmol) in benzene (1 mL) over 15 min. The reaction was stirred for 1 h under reflux, cooled to room temperature, concentrated and diluted with EtOAc. The organic phase was washed with satd. aqueous NaHCO₃ and brine then dried over MgSO₄. Evaporation of solvent gave the crude material which was re-dissolved in THF (2 mL), and treated with solid KF (100 mg) with stirring for 1 h, to remove the tin byproducts. Evaporation of solvent gave the crude material which was purified by silica gel flash chromatography, eluting with 7% EtOAc in hexanes to afford (2S,3S,4aR,8S,8aR)-tert-butyl 2,3-dimethoxy-2,3,8-trimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (57 mg, 55%) as a white foam.

[00116] The above material (57 mg, 0.15 mmol) was dissolved in TFA/H₂O (9:1, 2 mL) and the reaction mixture was stirred for 2 h at room temperature then evaporated to dryness. The crude material was purified by silica gel flash chromatography, eluting with 5:10:85 NH₄OH:MeOH:DCM to afford (6R,7R,8S)-8-methyl-4-azaspiro[2.5]octane-6,7-diol (21 mg, 91%) as a white foam. ¹H NMR (400 MHz, *d*-MeOH) δ 3.50-3.42 (m, 1H), 3.07 (dd, *J* = 8, 9.6 Hz, 1H), 3.00 (dd, *J* = 5.2, 12.4 Hz, 1H), 2.5 (dd, *J* = 10.8, 12.4 Hz, 1H), 1.94-1.86 (m, 1H), 0.72 (d, *J* = 6.8 Hz, 3H), 0.7-0.66 (m, 1H), 0.63-0.58 (m, 1H), 0.52-0.47 (m, 1H), 0.38-0.33 (m, 1H); MS *m/z* 158.30 (M+1, 100%).

Example 2

(6R,7R,8R)-8-(hydroxymethyl)-4-azaspiro[2.5]octane-6,7-diol

[00117] A stock triisopropoxymethyltitanium solution (0.5 M) was prepared as follows: To a stirred, pre-cooled (ice bath) flask charged with titanium (IV) isopropoxide (2.68 mL, 9.0 mmol) was added dropwise titanium tetrachloride (0.32 mL, 3.0 mmol). The mixture was allowed to warm to room temperature and stirred for 5 min. THF (13.5 mL) was added and stirring was continued at room temperature for 30 min. The reaction mixture was cooled to 0°C and MeLi (1.6 M in diethyl ether, 7.5 mL, 12 mmol) was added. During the addition LiCl precipitated and the color of the suspension changed from orange to bright yellow.

After 1 h, a portion of the resulting triisopropoxymethyltitanium solution (0.5 M, 12.6 mL, 6.3 mmol) was transferred to a flask containing (2S,3S,4aS,5S,8R,8aR)-5-(benzyloxy)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-pyrano[3,4-b][1,4]dioxine-8-carbonitrile (PCT Int. Appl. No. WO 2008144773) (1.5 g, 4.2 mmol) in THF (20 mL) at room temperature, followed by the addition of ethyl magnesium bromide (3.0 M in Et₂O, 2.0 mL, 6.0 mmol). The resulting brown mixture was stirred 1 h at room temperature, then boron trifluoride etherate (1.0 mL, 8.1 mmol) was added and resulting mixture was stirred for an additional h at room temperature, then quenched by adding 2 N HCl (6.3 mL, 12.6 mmol), H₂O (30 mL) and then neutralized by addition of NaOH (3M, 5 mL, 15.0 mmol). The aqueous layer was extracted by EtOAc (3 x 100 mL) and the resulting organic solution was washed with water, brine, and dried over Na₂SO₄. The solvent was evaporated to give the crude material, which was purified by silica gel flash chromatography, eluting with 3% MeOH and 3% ammonium hydroxide in DCM to give (1-((2S,3S,4aS,5S,8R,8aR)-5-(benzyloxy)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-pyrano[3,4-b][1,4]dioxin-8-yl)cyclopropanamine as a white solid (1.4 g, 75%).

¹H NMR (500 MHz, CDCl₃) δ 7.41 (d, *J* = 6 Hz, 2H), 7.34 (dd, *J* = 7.0 Hz, 7.0 Hz, 2H), 7.28 (d, *J* = 7.0 Hz, 1H), 4.88 (d, *J* = 3.5 Hz, 1H), 4.70 (d, *J* = 12.5 Hz, 1H), 4.66 (d, *J* = 12.5 Hz, 1H), 4.45 (dd, *J* = 11 Hz, 5.5 Hz, 1H), 4.42 (dd, *J* = 11 Hz, 3.5 Hz, 1H), 3.92 (dd, *J* = 12.3 Hz, 3.5 Hz, 1H), 3.60 (d, *J* = 12 Hz, 1H), 3.25 (s, 3H), 3.23 (s, 3H), 2.19-1.80 (broad, NH₂), 1.67-1.60 (m, 1H), 1.34 (s, 3H), 1.29 (s, 3H), 0.69-0.52 (m, 4H); MS *m/z* 394.22 (M+1, 100%).


[00118] The above material (400 mg, 1.5 mmol) was dissolved in MeOH (30 mL), then 5 drops of acetic acid were added followed by addition of Pd(OH)₂ (20% palladium hydroxide on carbon wet, 100 mg). Hydrogen gas in a balloon was bubbled through the reaction for 20 min and the mixture was then stirred under hydrogen (1 atm.) at room temperature for 8 h.

5 During the reaction period, hydrogen gas was bubbled through the reaction mixture three times so that the solution was continually saturated with hydrogen. Filtration of the crude reaction through Celite® 545 and evaporation of solvent gave the crude material which was purified by silica gel flash chromatography, eluting with 5% MeOH in EtOAc to afford ((2S,3S,4aR,8R,8aR)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropan]-8-yl)methanol as a white solid (284 mg, 65%). ¹H NMR (500 MHz, CDCl₃) δ 3.82 (dd, *J* = 10 Hz, 10 Hz, 1H), 3.71-3.66 (m, 1H), 3.45 (dd, *J* = 11 Hz, 8 Hz, 1H), 3.30 (s, 3H), 3.29 (s, 3H), 3.25 (dd, *J* = 11 Hz, 3.5 Hz, 1H), 2.95 (dd, *J* = 13 Hz, 5 Hz, 1H), 2.72 (dd, *J* = 13 Hz, 11 Hz, 1H), 2.25-2.20 (m, 1H), 2.25-2.20 (broad, NH), 1.33 (s, 3H), 1.30 (s, 3H), 0.80-0.75 (m, 1H), 0.57-0.52 (m, 1H), 0.46-0.37 (m, 2H); MS *m/z* 288.177 (M+1, 100%).

[00119] The above material (30 mg, 0.1 mmol) was dissolved in TFA/H₂O (9:1, 1 mL) and the reaction mixture was stirred for 2 h at room temperature then evaporated to dryness. Et₂O (2.0 mL) was added to the crude material, and a white solid formed which was then collected and dried under high vacuum to give (6R,7R,8R)-8-(hydroxymethyl)-4-azaspiro[2.5]octane-6,7-diol as the TFA salt (11 mg). ¹H NMR (400 MHz, *d*₄-MeOH) δ 3.92 (dd, *J* = 11.6 Hz, 5.6 Hz, 1H), 3.88-3.86 (broad, 2H), 3.79 (dd, *J* = 11.2 Hz, 6.0 Hz, 1H), 3.54-3.48 (m, 1H), 3.06-3.03 (broad, 1H), 1.73-1.67 (broad 1H), 1.16-1.05 (m, 2H), 1.04-0.97 (m, 1H), 0.93-0.55 (m, 1H); MS *m/z* 174.11 (M+1, 100%).

Example 3

25 (6R,7R,8S)-8-(fluoromethyl)-4-azaspiro[2.5]octane-6,7-diol



[00120] 2,2,2-Trifluoro-1-((2S,3S,4aR,8R,8aR)-8-(hydroxymethyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropan]-6(3H)-yl)ethanone (0.103 g, 0.27 mmol) was taken up in DCM (12 mL) and cooled to -78° C.


30 DAST (0.18 mL, 1.4 mmol) was added dropwise while stirring at -78° C. After the addition,

the cooling bath was removed and reaction mixture stirred at room temperature overnight. The reaction was diluted with satd. aqueous NaHCO₃ solution (10 mL). The DCM layer was separated, dried over anhydrous Na₂SO₄ and concentrated. The crude residue was purified by automatic flash column chromatography (EtOAc/ hexanes, 1:4) to provide 2,2,2-trifluoro-1-
5 ((2S,3S,4aR,8R,8aR)-8-(hydroxymethyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropan]-6(3H)-yl) ethanone (0.076 g, 72.9%) as mixture of rotamers. ES/MS: 408.13 [M + Na].

[00121] The above material (0.101 g, 0.26 mmol) was taken up in 7:3 MeOH:H₂O (10 mL) followed by the addition of K₂CO₃ (0.360 g, 2.6 mmol) and stirred at room temperature
10 overnight. The reaction mixture was concentrated and diluted with EtOAc (50 mL) which was subsequently washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The crude product was purified on silica gel by automatic flash column chromatography (EtOAc, 100%) to provide (2S,3S,4aR,8S,8aR)-8-(fluoromethyl)-2,3-dimethoxy-2,3-
15 dimethylhexahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane] (0.055 g, 73%) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ 4.53- 4.39 (ddd, *J* = 47.4, 10.0, 5.1 Hz, 1H), 4.33- 4.19 (ddd, *J* = 47.9, 9.95, 1.05 Hz, 1H), 3.84- 3.79 (dd, *J* = 10.7, 9.6 Hz, 1H), 3.73- 3.66 (m, 1H), 3.28 (s, 3H), 3.24 (s, 3H), 2.99- 2.93 (dd, *J* = 12.8, 4.9 Hz, 1H), 2.79-2.73 (dd, *J* = 12.5, 11.4 Hz, 1H), 2.23- 2.11 (ddd, *J* = 32.0, 11.0, 4.8 Hz, 1H), 1.31 (s, 3H), 1.30 (s, 3H), 0.88-0.83 (m, 1H), 0.81- 0.76 (m, 1H), 0.64- 0.59 (m, 1H), 0.54- 0.48 (m, 1H). ES/MS:
20 290.17 [M + 1].

[00122] The above material (0.055 g, 0.19 mmol) was taken up in 90% TFA/ H₂O (10 mL) at 0°C and stirred at this temperature for 1 h and slowly warmed to room temperature over the next 1.5 h. The reaction mixture was evaporated to dryness and 2M NH₃/ MeOH (5 mL) solution was added to neutralize the reaction. The reaction mixture was again concentrated
25 and the crude residue was purified by silica gel column chromatography (DCM/MeOH, 85:15) to provide (6R,7R,8S)-8-(fluoromethyl)-4-azaspiro[2.5]octane-6,7-diol (0.028 g, 84.2%) as a white solid. ¹H NMR (400 MHz, MeOD) δ 4.62- 4.53 (ddd, *J* = 18.8, 10.0, 6.0 Hz, 1H), 4.50- 4.41 (ddd, *J* = 18.4, 10.0, 6.0 Hz, 1H), 3.61- 3.51 (m, 2H), 3.14- 3.09 (dd, *J* = 12.6, 4.0 Hz, 1H), 2.67-2.60 (dd, *J* = 12.7, 8.5 Hz, 1H), 2.05- 1.92 (m, 1H), 0.93- 0.87 (m, 30 1H), 0.86- 0.80 (m, 1H), 0.71- 0.65 (m, 1H), 0.58- 0.51 (m, 1H). ES/MS: 176.10 [M + 1].

Example 4

(6R,7R,8S)-8-(difluoromethyl)-4-azaspiro[2.5]octane-6,7-diol

[00123] To a solution of ((2S,3S,4aR,8R,8aR)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropan]-8-yl)methanol (170 mg, 0.60 mmol) and triethylamine (0.4 mL, 2.77 mmol) in toluene (3 mL) was added TFAA (0.12 mL, 0.88 mmol) at 0°C. The mixture was stirred for 30 min at room temperature then THF and satd. aqueous NaHCO₃ (1:1, 20 mL) were added. The resulting suspension was vigorously stirred for 0.5 h and then extracted with EtOAc (3 x 30 mL). The organic phase was washed with brine and dried over MgSO₄. Evaporation of solvent gave the crude material which was purified by silica gel flash chromatography, eluting with 30% EtOAc in hexanes to afford 2,2,2-trifluoro-1-((2S,3S,4aR,8R,8aR)-8-(hydroxymethyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropan]-6(3H)-yl)ethanone as a white solid (140 mg, 60%).

[00124] To a solution of the above material (140 mg, 0.37 mmol) in DCM (3 mL) was added DMP (232 mg, 0.55 mmol). The mixture was stirred for 1 h at room temperature then diluted with EtOAc (20 mL). The organic phase was washed with satd. aqueous NaHCO₃ and brine, then dried over MgSO₄. Evaporation of solvent gave the crude material which was purified by silica gel flash chromatography, eluting with 20% EtOAc in hexanes to afford (2S,3S,4aR,8S,8aR)-2,3-dimethoxy-2,3-dimethyl-6-(2,2,2-trifluoroacetyl)hexahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-8-carbaldehyde as a white solid (106 mg, 76%).

[00125] The above material (106 mg, 0.28 mmol) was taken up in DCM (4 mL) and cooled to -15°C. DAST (0.11 mL, 0.83 mmol) was added dropwise while stirring at -15°C. After the addition, the cooling bath was removed and the reaction mixture was stirred at room temperature overnight. The reaction was diluted with satd. aqueous NaHCO₃ solution (10 mL). The DCM layer was separated, dried over anhydrous Na₂SO₄ and concentrated. The crude residue was purified on silica gel by automatic flash column chromatography eluting with 30% EtOAc in hexanes to provide 1-((2S,3S,4aR,8S,8aR)-8-(difluoromethyl)-2,3-


dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropan]-6(3H)-yl)-2,2,2-trifluoroethanone (88 mg, 81%) as a white foam.

[00126] The above material (88 mg, 0.22 mmol) was taken up in 1:1 MeOH:H₂O (4 mL) then solid K₂CO₃ (300 mg, 2.2 mmol) was added and the resulting mixture was stirred at room temperature overnight. The reaction mixture was concentrated and diluted with EtOAc (50 mL) then washed with brine, dried over anhydrous Na₂SO₄ and concentrated. The crude product was purified on silica gel by automatic flash column chromatography eluting with 50% EtOAc in hexanes to provide (2S,3S,4aR,8S,8aR)-8-(difluoromethyl)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane] (58 mg, 87%) as a white foam.

[00127] The above material (58 mg, 0.19 mmol) was dissolved in TFA/H₂O (9:1, 2 mL) and the reaction mixture was stirred for 2 h at room temperature then evaporated to dryness. The crude material was purified by silica gel flash chromatography, eluting with 5:10:85 NH₄OH:MeOH:DCM to afford (6R,7R,8S)-8-(difluoromethyl)-4-azaspiro[2.5]octane-6,7-diol (26 mg, 69%) as a white solid. ¹H NMR (400 MHz, *d*-MeOH) δ 6.37 (ddd, *J* = 56.4, 56.4, 6.4 Hz, 1H), 3.92 (t, *J* = 4.8 Hz, 1H), 3.57 (dd, *J* = 7.6, 4.4 Hz, 1H), 3.17 (dd, *J* = 13.6, 2.8 Hz, 1H), 2.66 (dd, *J* = 13.2, 4.8 Hz, 1H), 1.74-1.62 (m, 1H), 0.78-0.70 (m, 2H), 0.65-0.61 (m, 1H), 0.56-0.53 (m, 1H); MS *m/z* 194.09 (M+1, 100%).

Example 5

(6R,7R,8S)-8-(chloromethyl)-4-azaspiro[2.5]octane-6,7-diol




[00128] To a solution of ((2S,3S,4aR,8R,8aR)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropan]-8-yl)methanol (284 mg, 0.99 mmol) and DIPEA (0.27 mL, 1.47 mmol) in DCM (10 mL) was added Boc₂O (237 mg, 1.10 mmol). The mixture was stirred overnight and diluted with EtOAc (100 mL). The organic phase was washed with saturated NH₄Cl and brine, then dried over anhydrous MgSO₄. Evaporation of solvent gave the crude material which was purified by silica gel column chromatography, eluting with 30% EtOAc in hexanes to afford (2S,3S,4aR,8R,8aR)-tert-butyl 8-

(hydroxymethyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white solid (270 mg, 70%).

[00129] To a solution of the above material (137 mg, 0.35 mmol) and Ph₃P (276 mg, 1.05 mmol) in DCM (2 mL) was added CCl₄ (0.4 mL, 4.10 mmol). The reaction mixture was stirred overnight and then concentrated. The crude material was purified by silica gel column chromatography, eluting with 20% EtOAc in hexanes to afford (2S,3S,4aR,8S,8aR)-tert-butyl 8-(chloromethyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white solid (143 mg, 100%). This compound was dissolved in TFA/H₂O (9:1, 2 mL) and the reaction mixture was stirred for 2 h at room temperature then evaporated to dryness. The crude material was purified by silica gel column chromatography, eluting with 5:10:85 NH₄OH:MeOH:DCM to afford (6R,7R,8S)-8-(chloromethyl)-4-azaspiro[2.5]octane-6,7-diol as a white solid (59 mg, 85%). ¹H NMR (400 MHz, *d*₄-MeOH) δ 3.90 (dd, *J* = 11.6 Hz, 4.8 Hz, 1H), 3.66 (dd, *J* = 7.0 Hz, *J* = 7.0 Hz, 1H), 3.57-3.50 (m, 2H), 3.06 (dd, *J* = 13.2 Hz, *J* = 4 Hz, 1H), 2.60 (dd, *J* = 13.2 Hz, *J* = 7.6 Hz, 1H), 1.93-1.83 (m, 1H), 0.92-0.82 (m, 1H), 0.82-0.78 (m, 1H), 0.67-0.62 (m, 1H), 0.51-0.46 (m, 1H); MS *m/z* 191.07 (M+1, 100%).

Example 6

(6R,7R,8R)-8-(methoxymethyl)-4-azaspiro[2.5]octane-6,7-diol




[00130] To a solution of (2S,3S,4aR,8R,8aR)-tert-butyl 8-(hydroxymethyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (104 mg, 0.27 mmol) in THF (3 mL) was added NaH (57%-63% in mineral oil, 21 mg, 0.54 mmol) followed by MeI (0.1 mL, 1.5 mmol). The mixture was stirred overnight at room temperature, concentrated and diluted with EtOAc (20 mL). The organic phase was washed with satd. aqueous NaHCO₃ and brine, then dried over MgSO₄. Evaporation of solvent gave the crude material which was purified by silica gel flash chromatography, eluting with 30% EtOAc in hexanes to afford (2S,3S,4aR,8R,8aR)-tert-butyl 2,3-dimethoxy-8-(methoxymethyl)-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (96 mg, 89%) as a white foam.

[00131] The above material (98 mg, 0.24 mmol) was dissolved in TFA/H₂O (9:1, 2 mL) and the reaction mixture was stirred for 2 h at room temperature then evaporated to dryness. The crude material was purified by silica gel flash chromatography, eluting with 5:10:85 NH₄OH:MeOH:DCM to afford ((6R,7R,8R)-8-(methoxymethyl)-4-azaspiro[2.5]octane-6,7-diol (38 mg, 83%). ¹H NMR (400 MHz, *d*-MeOH) δ 3.62-3.44 (m, 3H), 3.30 (dd, *J* = 10, 6.4 Hz, 1H), 3.27 (s, 3H), 3.01 (dd, *J* = 4.4, 9.2 Hz, 1H), 2.52 (dd, *J* = 9.2, 12.8 Hz, 1H), 1.96-1.85 (m, 1H), 0.89-0.84 (m, 1H), 0.79-0.74 (m, 1H), 0.58-0.52 (m, 1H), 0.42-0.38 (m, 1H); MS *m/z* 188.13 (M+1, 100%).

Example 7

10 **(6R,7S,8S)-8-methoxy-4-azaspiro[2.5]octane-6,7-diol**



[00132] To a solution of (2S,3S,4aR,8S,8aR)-tert-butyl 8-formyl-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (773 mg, 2.01 mmol) in DCM (20 mL) was added MCPBA (675 mg, 77% pure, 15 3.00 mmol). The mixture was stirred for 24 h at room temperature, then diluted with EtOAc. The organic solution was washed with satd. NaHCO₃, brine, dried over MgSO₄. Evaporation of solvent gave the crude which was purified by silica gel flash chromatography, eluting with 10% first then 30% EtOAc in hexanes to afford (2S,3S,4aR,8S,8aR)-6-(tert-butoxycarbonyl)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-spiro[[1,4]dioxino[2,3- 20 c]pyridine-7,1'-cyclopropane]-8-carboxylic acid (296 mg, 40%) and (2S,3S,4aR,8S,8aS)-tert-butyl 8-(formyloxy)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (169 mg, 20%) as white solids.

[00133] To a solution of (2S,3S,4aR,8S,8aS)-tert-butyl 8-(formyloxy)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)- 25 carboxylate (169 mg, 0.42 mmol) in MeOH and H₂O (3:1, 4 mL) was added KOH (380 mg, 6.8 mmol). The mixture was heated at reflux for 1 h, cooled to room temperature and diluted with EtOAc. The organic solution was washed with satd. NaHCO₃, brine, dried over MgSO₄. Evaporation of solvent gave the crude which was purified by silica gel flash chromatography, eluting with 20% of EtOAc in hexanes to afford (2S,3S,4aR,8S,8aR)-tert-butyl 8-hydroxy-


2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (158 mg, 100%) as a white solid.

[00134] To a solution of the above material (53 mg, 0.14 mmol) in THF (1 mL) was added NaH (11 mg, 57% - 64%, 0.27 mmol), followed by addition of MeI (0.05 mL, 0.71 mmol).

- 5 The mixture was warmed to 50 °C for 2 h, cooled to room temperature and diluted with EtOAc. The organic solution was washed with satd. NaHCO₃, brine, dried over MgSO₄. Evaporation of solvent gave the crude which was purified by silica gel flash chromatography, eluting with 10% of EtOAc in hexanes to afford (2S,3S,4aR,8S,8aS)-tert-butyl 2,3,8-trimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-
- 10 6(3H)-carboxylate as a white solid. The crude material was dissolved in TFA/H₂O (9:1, 2 mL) and the reaction mixture was stirred for 2 h at room temperature then evaporated to dryness. The crude was purified by silica gel flash chromatography eluting with 5:10:85 of NH₃ H₂O:MeOH:DCM to afford (6R,7S,8S)-8-methoxy-4-azaspiro[2.5]octane-6,7-diol (22 mg, 89% over 2 steps). ¹H NMR (400 MHz, *d*-MeOH) δ 3.35-3.47 (m, 1H), 3.49 (s, 3H),
- 15 3.37-3.38 (m, 2H), 3.14 (d, *J* = 8.4 Hz, 1H), 2.95 (dd, *J* = 4.8, 12.8 Hz, 1H), 2.47 (dd, *J* = 10, 12.8 Hz, 1H), 0.70-0.65 (m, 2H), 0.57-0.54 (m, 1H), 0.40-0.34 (m, 1H); *m/z* 174.12 (M+1, 100%).

Example 8

(6R,7R,8R)-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carbonitrile




- 20 [00135] To a solution of (2S,3S,4aR,8S,8aR)-tert-butyl 8-formyl-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (316 mg, 0.82 mmol) and NH₂OH HCl salt (286 mg, 3.77 mmol) in EtOH/H₂O (1:1, 6 mL) was added NaHCO₃ (276 mg, 3.28 mmol). The mixture was stirred overnight at
- 25 room temperature, concentrated and diluted with EtOAc (30 mL). The organic solution was washed with satd. aqueous NaHCO₃ and brine, then dried over MgSO₄. Evaporation of solvent gave the crude (2S,3S,4aR,8R,8aR)-tert-butyl 8-((hydroxyimino)methyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-
- 30 6(3H)-carboxylate (281 mg, 85%) as a mixture of trans and cis isomers, which was used directly in the next step.

[00136] To a solution of the above material (281 mg, 0.70 mmol) in pyridine (3 mL) at 0°C was added MsCl (0.4 mL, 5.2 mmol). The mixture was stirred for 1 h at 0°C then diluted with EtOAc (30 mL). The organic phase was washed with satd. aqueous NaHCO₃ and brine, then dried over MgSO₄. Evaporation of solvent gave the crude material which was purified
 5 by a silica gel flash chromatography, eluting with 10% EtOAc in hexanes to afford (2S,3S,4aR,8R,8aR)-tert-butyl 8-cyano-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (229 mg, 86%) as a white foam.

[00137] The above material (229 mg, 0.60 mmol) was dissolved in TFA/H₂O (9:1, 2 mL) and
 10 the reaction mixture was stirred for 2 h at room temperature then evaporated to dryness. The crude material was purified by a silica gel flash chromatography, eluting with 5:10:85 NH₄OH:MeOH:DCM to afford (6R,7R,8R)-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carbonitrile (63 mg, 63%) as a white solid. ¹H NMR (500 MHz, *d*-MeOH) δ 3.60 (t, *J* = 9 Hz, 1H), 3.43-3.37 (m, 1H), 3.09 (d, *J* = 9.5 Hz, 1H), 3.01 (dd, *J* = 13, 5 Hz, 1H), 2.53 (dd, *J* =
 15 13, 10.5 Hz, 1H), 0.91-0.78 (m, 3H), 0.67-0.63 (m, 1H); MS *m/z* 169.10 (M+1, 100%).

Example 9


(6R,7R,8S)-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carboxylic acid



[00138] (2S,3S,4aR,8S,8aR)-6-(tert-butoxycarbonyl)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-8-carboxylic
 20 acid was dissolved in TFA/H₂O (9:1, 2 mL) and reaction mixture was stirred for 2 h at room temperature then evaporated to dryness. The crude was washed with Et₂O and dried under high vacuum to give (6R,7R,8S)-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carboxylic acid as the TFA salt (23 mg, 50%). ¹H NMR (400 MHz, *d*-MeOH) δ 4.32 (br s, 1H), 3.93 (br s, 1H),
 25 3.59 (d, *J* = 12.8 Hz, 1H), 3.15 (d, *J* = 12 Hz, 1H), 2.45 (br s, 1H), 1.02-1.09 (m, 2H), 1.01-0.92 (m, 2H); *m/z* 188.09 (M+1, 100%).

Example 10

(6R,7R,8S)-6,7-dihydroxy-N-methyl-4-azaspiro[2.5]octane-8-carboxamide




[00139] To a solution of (2S,3S,4aR,8S,8aR)-6-(tert-butoxycarbonyl)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-8-carboxylic acid (85 mg, 0.21 mmol), HOBt (43 mg, 0.318 mmol), methyl amine hydrochloride salt (22 mg, 0.318 mmol) and *i*-Pr₂NEt (0.1 mL, 0.55 mmol) in DMF (2 mL) was added HATU (121 mg, 0.32 mmol). The mixture was stirred for 24 h at room temperature then diluted with EtOAc. The organic solution was washed with satd. NaHCO₃, brine, dried over MgSO₄.

Evaporation of solvent gave the crude which was purified by silica gel flash chromatography, eluting with 30% EtOAc in hexanes to afford desired amide product as a white solid. This intermediate was dissolved in TFA/H₂O (9:1, 2 mL), stirred for 2 h at room temperature then evaporated to dryness. The crude was purified by silica gel flash chromatography, eluting with 5:10:85 of NH₃ H₂O:MeOH:DCM to afford (6R,7R,8S)-6,7-dihydroxy-N-methyl-4-azaspiro[2.5]octane-8-carboxamide (20 mg, 48% over two steps) as a white solid. ¹H NMR (400 MHz, *d*-MeOH) δ 3.85 (dd, *J* = 8.0, 9.2 Hz, 1H), 3.55-3.50 (m, 1H), 3.05 (dd, *J* = 4.8, 12.8 Hz, 1H), 2.7 (s, 3H), 2.64-2.58 (m, 2H), 0.95-0.89 (m, 1H), 0.70-0.64 (m, 1H), 0.56-0.50 (m, 1H); *m/z* 201.13 (M+1, 100%).

Example 11


(6R,7R,8S)-N-cyclopropyl-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carboxamide



[00140] To a solution of (2S,3S,4aR,8S,8aR)-6-(tert-butoxycarbonyl)-2,3-dimethoxy-2,3-dimethylhexahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-8-carboxylic acid (85 mg, 0.21 mmol), HOBt (43 mg, 0.318 mmol), cyclopropylamine (0.026 mL, 0.318 mmol) and *i*-Pr₂NEt (0.1 mL, 0.55 mmol) in DMF (2 mL) was added HATU (121 mg, 0.32 mmol). The mixture was stirred for 24 h at room temperature then diluted with EtOAc. The organic solution was washed with satd. NaHCO₃, brine, dried over MgSO₄. Evaporation of

solvent gave the crude which was purified by silica gel flash chromatography, eluting with 30% EtOAc in hexanes to afford desired amide product as a white solid. This intermediate was dissolved in TFA/H₂O (9:1, 2 mL), stirred for 2 h at room temperature then evaporated to dryness. The crude was purified by silica gel flash chromatography, eluting with 5:10:85 of NH₃·H₂O:MeOH:DCM to afford (6R,7R,8S)-N-cyclopropyl-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carboxamide (25 mg, 52% over two steps) as a white solid. ¹H NMR (400 MHz, *d*-MeOH) δ 3.84 (dd, *J* = 8.4, 9.2 Hz, 1H), 3.53-3.47 (m, 1H), 3.04 (dd, *J* = 5.2, 12.8 Hz, 1H), 2.65-2.55 (m, 3H), 0.96-0.88 (m, 1H), 0.75-0.62 (m, 3H), 0.55-0.42 (m, 4H); *m/z* 227.15 (M+1, 100%).


10

Example 12**(6R,7R,8S)-8-ethyl-4-azaspiro[2.5]octane-6,7-diol**

15

[00141] To a solution of (6R,7R,8S)-8-vinyl-4-azaspiro[2.5]octane-6,7-diol (50 mg, 0.29 mmol) in MeOH (3 mL) was added Pd/C (10% on activated carbon, 20 mg). Hydrogen under atmospheric pressure (balloon) was passed through the reaction for 1 h at room temperature. Filtration of the crude reaction mixture through Celite®-545 and evaporation of solvent gave the crude material which was purified by silica gel flash chromatography, eluting with 5:10:85 NH₄OH:MeOH:DCM to afford (6R,7R,8S)-8-ethyl-4-azaspiro[2.5]octane-6,7-diol as a white solid (25 mg, 49%). ¹H NMR (400 MHz, MeOH) δ 3.50-3.33 (m, 1H), 3.35-3.31 (m, 1H), 3.03 (dd, *J* = 4.8, 12.8 Hz, 1H), 2.55 (dd, *J* = 12.4, 13.2 Hz, 1H), 1.65-1.56 (m, 1H), 1.47-1.43 (m, 1H), 1.01-0.90 (m, 4H), 0.71-0.66 (m, 1H), 0.61-0.56 (m, 1H), 0.52-0.48 (m, 1H), 0.42-0.37 (m, 1H); MS *m/z* 172.13 (M+1, 100%).

20

Example 13**(6R,7R,8S)-8-propyl-4-azaspiro[2.5]octane-6,7-diol**

25


[00142] To a solution of ((2S,3S,4aR,8S,8aR)-tert-butyl 2,3-dimethoxy-2,3-dimethyl-8-(prop-1-yn-1-yl)tetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-

carboxylate (170 mg, 0.43 mmol) in MeOH (3 mL) was added Pd/C (10% on activated carbon, 20 mg). Hydrogen (balloon) was passed through the solution for 48 h at room temperature. Filtration of crude reaction through celite 545 and evaporation of solvent gave the crude which was purified by silica gel flash chromatography, eluting with 15% EtOAc in hexanes afford (2S,3S,4aR,8S,8aR)-tert-butyl 2,3-dimethoxy-2,3-dimethyl-8-propyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white solid (73 mg, 41%).

[00143] The above material (74 mg, 0.2 mmol) was dissolved in TFA/H₂O (9:1, 2 mL) and reaction mixture was stirred for 2 h at room temperature then evaporated to dryness. The crude was purified by silica gel flash chromatography, eluting with 5:10:85 of NH₄OH:MeOH:DCM to afford (6R,7R,8S)-8-propyl-4-azaspiro[2.5]octane-6,7-diol (31 mg, 100%). ¹H NMR (400 MHz, *d*-MeOH) δ 3.52-3.47 (m, 1H), 3.38-3.31 (1H, overlapped with MeOH peak), 3.05 (dd, *J* = 4.4, 12.8 Hz, 1H), 2.58 (dd, *J* = 8.8, 12.8 Hz, 1H), 1.66-1.31 (m, 4H), 1.01-0.82 (m, 1H), 0.9 (t, *J* = 7.2 Hz, 3H), 0.7-0.65 (m, 1H), 0.63-0.58 (m, 1H), 0.56-0.50 (m, 1H), 0.45-0.40 (m, 1H); *m/z* 186.16 (M+1, 100%).

Example 14

(6R,7R,8S)-8-(2-fluoroethyl)-4-azaspiro[2.5]octane-6,7-diol




[00144] To a solution of (2S,3S,4aR,8S,8aR)-tert-butyl 8-(2-fluorovinyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (40 mg, 0.10 mmol) in MeOH (20 mL) was added Pd/C (10 wt.%, 22 mg, 0.02 mmol) and the mixture was treated with hydrogen (1 atm) for 2 days. Catalyst was filtered off through celite and the solvent was evaporated under reduced pressure. The residue was purified by silica gel flash chromatography affording (2S,3S,4aR,8S,8aR)-tert-butyl 8-(2-fluoroethyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a light yellow oil (26 mg, 65%). MS, (ES, *m/z*) [M+Na]⁺ 426.23.

[00145] A mixture of TFA (2 mL) and H₂O (0.2 mL) was cooled to 0 °C, added to (2S,3S,4aR,8S,8aR)-tert-butyl 8-(2-fluoroethyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-

spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (25 mg, 0.062 mmol) at 0 °C. The mixture was stirred at 0 °C for 10 min, then room temperature for 4 h. TFA was removed under vacuum. The residue was purified by silica gel flash chromatography (using 70:20:2 DCM/MeOH/NH₄OH as eluent) to give (6R,7R,8S)-8-(2-fluoroethyl)-4-azaspiro[2.5]octane-6,7-diol (8.5 mg, 72%). ¹H NMR (400 MHz, CD₃OD) δ 4.68-4.38 (m, 1H), 3.52-3.45 (m, 1H), 3.38-3.32 (m, 1H), 3.04 (dd, *J* = 4.4, 12.8 Hz, 1H), 2.56 (dd, *J* = 8.8, 12.8 Hz, 1H), 1.93-1.78 (m, 1H), 1.75-1.67 (m, 1H), 1.45-1.25 (m, 1H), 0.75-0.68 (m, 1H), 0.63-0.56 (m, 1H), 0.54-0.41 (m, 2H); MS, (ES, *m/z*) [M+H]⁺ 190.13.

Example 15


10 (6R,7R,8S)-8-(2,2-difluoroethyl)-4-azaspiro[2.5]octane-6,7-diol



[00146] To a solution of (2S,3S,4aR,8S,8aR)-tert-butyl 8-(2,2-difluorovinyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (60 mg, 0.14 mmol) in MeOH (20 mL) was added Pd/C (10 wt.%, 22 mg, 0.02 mmol) and the mixture was treated with hydrogen (1 atm) for 4 days. Catalyst was filtered off through celite and the solvent was evaporated under reduced pressure. The residue was purified by silica gel flash chromatography affording (2S,3S,4aR,8S,8aR)-tert-butyl 8-(2,2-difluoroethyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a light yellow oil (47 mg, 78%). MS, (ES, *m/z*) [M+Na]⁺ 444.22.

[00147] TFA (2 mL) and H₂O (0.2 mL) mixture was cooled to 0 °C, added to the above material (42 mg, 0.10 mmol) at 0 °C. The mixture was stirred at 0 °C for 10 min, then room temperature for 4 h. TFA was removed under vacuum. The residue was purified by silica gel flash chromatography (using 70:20:2 DCM/MeOH/NH₄OH as eluent) to give (6R,7R,8S)-8-(2,2-difluoroethyl)-4-azaspiro[2.5]octane-6,7-diol (12 mg, 58%). ¹H NMR (400 MHz, CD₃OD) δ 6.30-5.95 (m, 1H), 3.53-3.46 (m, 1H), 3.36 (t, *J* = 7.6 Hz, 1H), 3.04 (dd, *J* = 4.4, 12.8 Hz, 1H), 2.56 (dd, *J* = 8.8, 12.8 Hz, 1H), 2.07-1.80 (m, 2H), 1.55-1.37 (m, 1H), 0.78-0.71 (m, 1H), 0.66-0.58 (m, 1H), 0.53-0.44 (m, 2H); MS, (ES, *m/z*) [M+H]⁺ 208.12.


Example 16

(6R,7R,8S)-8-vinyl-4-azaspiro[2.5]octane-6,7-diol

[00148] To a suspension of methyl triphenylphosphonium bromide (904 mg, 2.40 mmol) in THF (20 mL) at 0°C was added n-BuLi (1.6 M in hexane, 1.24 mL, 2.00 mmol) and the resulting yellow suspension was stirred for 10 min at 0°C, then a solution of (2S,3S,4aR,8S,8aR)-tert-butyl-8-formyl-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (191 mg, 0.50 mmol) in THF (1 mL) was added. The resulting mixture was stirred for 1 h at room temperature then diluted with EtOAc (30 mL) and the organic phase was washed with satd. aqueous NaHCO₃ and brine then dried over MgSO₄. Evaporation of solvent gave the crude material which was purified by silica gel flash chromatography, eluting with 10% EtOAc in hexanes to afford (2S,3S,4aR,8S,8aR)-tert-butyl 2,3-dimethoxy-2,3-dimethyl-8-vinyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (170 mg, 90%) as a white foam.

[00149] The above material (170 mg, 0.44 mmol) was dissolved in TFA/H₂O (9:1, 2 mL) and the reaction mixture was stirred for 2 h at room temperature then evaporated to dryness. The crude material was purified by silica gel flash chromatography, eluting with 5:10:85 of NH₄OH:MeOH:DCM to afford (6R,7R,8S)-8-vinyl-4-azaspiro[2.5]octane-6,7-diol (71 mg, 91%) as a white foam. ¹H NMR (400 MHz, *d*-MeOH) δ 5.41-5.32 (m, 1H), 5.18-5.10 (m, 2H), 3.52-3.46 (m, 1H), 3.38-3.35 (m, 1H), 2.95 (dd, H = 5.2, 12.8 Hz, 1H), 2.56 (dd, J = 10.4, 12.8 Hz, 1H), 2.47 (t, J = 9.4 Hz, 1H), 0.59-0.43 (m, 4H); MS *m/z* 170.12 (M+1, 100%).

Example 17


(6R,7R,8S)-8-((Z)-2-fluorovinyl)-4-azaspiro[2.5]octane-6,7-diol

[00150] A freshly prepared solution of lithium diisopropylamide (2.26 mmol) in anhydrous THF (8 mL) was added slowly to a stirred suspension of (fluoromethyl)triphenylphosphonium tetrafluoroborate (0.86 g, 2.26 mmol) at -78 °C under N₂. The mixture was stirred at 0 °C for 15 min and then cooled to -78 °C. A solution of (2S,3S,4aR,8S,8aR)-tert-butyl 8-formyl-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (290 mg, 0.75 mmol) was added slowly. The mixture was allowed to warm up to room temperature and stirred for 18 h. The reaction was quenched with saturated aqueous ammonium chloride, and diluted with EtOAc. The organic layer was washed with water, brine, dried, and concentrated. The residue was purified by chromatography to give (2S,3S,4aR,8S,8aR)-tert-butyl 8-((Z)-2-fluorovinyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (19 mg, 6%) as oil. ¹H NMR (400 MHz, CDCl₃) δ 6.56 (ddd, *J* = 0.8, 4.8, 83.6 Hz, 1H), 4.30-4.00 (m, 2H), 3.75-3.60 (m, 2H), 3.32 (s, 3H), 3.27 (s, 3H), 3.28-3.25 (m, 1H), 2.87 (t, *J* = 11.2 Hz, 1H), 1.48 (s, 9H), 1.33 (s, 3H), 1.32 (s, 3H), 1.20-1.06 (br, 1H), 1.02-0.85 (m, 1H), 0.52-0.35 (m, 2H); MS, (ES, *m/z*) [M+Na]⁺ 424.22.

[00151] A mixture of TFA (2 mL) and H₂O (0.2 mL) was cooled to 0 °C, added to the above material (17 mg, 0.042 mmol) at 0 °C. The mixture was stirred at 0 °C for 10 min, then room temperature for 4 h. TFA was removed under vacuum. The residue was purified by silica gel flash chromatography (using 70:20:2 DCM/MeOH/NH₄OH as eluent) to give (6R,7R,8S)-8-((Z)-2-fluorovinyl)-4-azaspiro[2.5]octane-6,7-diol (4.8 mg, 60%). ¹H NMR (400 MHz, CD₃OD) δ 6.65 (ddd, *J* = 0.8, 4.8, 83.6 Hz, 1H), 4.55-4.35 (m, 1H), 3.54-3.46 (m, 1H), 3.27 (t, *J* = 9.6 Hz, 1H), 3.10-2.98 (m, 2H), 2.52 (dd, *J* = 10.8, 12.8 Hz, 1H), 0.60-0.48 (m, 3H), 0.42-0.34 (m, 1H); MS, (ES, *m/z*) [M+H]⁺ 188.12.

Example 18

(6R,7R,8S)-8-((E)-2-fluorovinyl)-4-azaspiro[2.5]octane-6,7-diol



[00152] A freshly prepared solution of lithium diisopropylamide (2.26 mmol) in anhydrous THF (8 mL) was added slowly to a stirred suspension of (fluoromethyl)triphenylphosphonium tetrafluoroborate (0.86 g, 2.26 mmol) at -78 °C under N₂. The mixture was stirred at 0 °C for 15 min and then cooled to -78 °C. A solution of (2S,3S,4aR,8S,8aR)-tert-


butyl 8-formyl-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (290 mg, 0.75 mmol) was added slowly. The mixture was allowed to warm up to room temperature and stirred for 18 h. The reaction was quenched with saturated aqueous ammonium chloride, and diluted with EtOAc. The organic layer was washed with water, brine, dried, and concentrated. The residue was purified by chromatography to give (2S,3S,4aR,8S,8aR)-tert-butyl 8-((E)-2-fluorovinyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (12 mg, 4%) as oil. ¹H NMR (400 MHz, CDCl₃) δ 6.59 (dd, *J* = 10.8, 84.4 Hz, 1H), 4.75-4.62 (m, 1H), 4.15-3.90 (br, 1H), 3.72-3.55 (m, 2H), 3.31 (s, 3H), 3.26 (s, 3H), 2.89 (t, *J* = 11.2 Hz, 1H), 2.65 (br, 1H), 1.46 (s, 9H), 1.33 (s, 6H), 1.23-1.10 (br, 1H), 1.07-0.95 (m, 1H), 0.60-0.40 (m, 2H); MS, (ES, *m/z*) [M+Na]⁺ 424.22.

[00153] A mixture of TFA (2 mL) and H₂O (0.2 mL) was cooled to 0 °C, added to the above material (12 mg, 0.030 mmol) at 0 °C. The mixture was stirred at 0 °C for 10 min, then room temperature for 4 h. TFA was removed under vacuum. The residue was purified by silica gel flash chromatography (using 70:20:2 DCM/MeOH/NH₄OH as eluent) to give (6R,7R,8S)-8-((E)-2-fluorovinyl)-4-azaspiro[2.5]octane-6,7-diol (3.2 mg, 57%). ¹H NMR (400 MHz, CD₃OD) δ 6.61 (dd, *J* = 10.8, 85.2 Hz, 1H), 4.94 (t, *J* = 10.8 Hz, 1H), 3.50-3.42 (m, 1H), 3.25 (t, *J* = 8.4 Hz, 1H), 3.01 (dd, *J* = 5.2, 10.8 Hz, 1H), 2.36 (dt, *J* = 2.0, 10.4 Hz, 1H), 0.61-0.40 (m, 4H); MS, (ES, *m/z*) [M+H]⁺ 188.11.

20

Example 19

(6R,7R,8S)-8-(2,2-difluorovinyl)-4-azaspiro[2.5]octane-6,7-diol



[00154] To a stirred solution of fresh made lithium diisopropylamide (5.1 mmol) in anhydrous THF (15 mL) was added diethyldifluoromethyl phosphonate (0.80 mL, 5.1 mmol) at -78 °C under N₂. The mixture was stirred at -78 °C for 2 h. A solution of (2S,3S,4aR,8S,8aR)-tert-butyl 8-formyl-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (278 mg, 0.72 mmol) was added slowly. After stirred at -78 °C for 30 min, the mixture was refluxed for 2 h, then stirred at room temperature for 18 h. The reaction was quenched with saturated aqueous ammonium chloride, and diluted with EtOAc. The organic layer was washed with water, brine, dried, and concentrated. The residue

30


was purified by chromatography to give (2S,3S,4aR,8S,8aR)-tert-butyl 8-(2,2-difluorovinyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (258 mg, 85%) as light yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 4.15-4.00 (br, 1H), 3.75-3.53 (m, 3H), 3.32 (s, 3H), 3.27 (s, 3H), 3.00-2.80 (br, 2H), 1.47 (s, 9H), 1.33 (s, 6H), 1.22-1.10 (br, 1H), 1.00-0.90 (m, 1H), 0.53-0.40 (m, 2H); MS, (ES, *m/z*) [M+Na]⁺ 442.21.

[00155] A mixture of TFA (2 mL) and H₂O (0.2 mL) was cooled to 0 °C, added to the above material (68 mg, 0.16 mmol) at 0 °C. The mixture was stirred at 0 °C for 10 min, then room temperature for 4 h. TFA was removed under vacuum. The residue was purified by silica gel flash chromatography eluting with 70:20:2 DCM/MeOH/NH₄OH to give (6R,7R,8S)-8-(2,2-difluorovinyl)-4-azaspiro[2.5]octane-6,7-diol (34 mg, 100%). ¹H NMR (400 MHz, CD₃OD) δ 4.04 (dd, *J* = 8.8, 24.8 Hz, 1H), 3.58-3.50 (m, 1H), 3.28 (t, *J* = 8.8 Hz, 1H), 3.09 (dd, *J* = 4.8, 12.4 Hz, 1H), 2.67 (t, *J* = 9.6 Hz, 1H), 2.60 (dd, *J* = 10.0, 12.4 Hz, 1H), 0.68-0.55 (m, 3H), 0.54-0.46 (m, 1H); MS, (ES, *m/z*) [M+H]⁺ 206.10.

15

Example 20

(6R,7R,8S)-8-ethynyl-4-azaspiro[2.5]octane-6,7-diol



[00156] To a solution of (2S,3S,4aR,8R,8aR)-tert-butyl 8-(hydroxymethyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (278.8 mg, 0.72 mmol) in DCM (7 mL) was added DMP (458 mg, 1.08 mmol). The mixture was stirred for 1 h at room temperature then diluted with EtOAc (30 mL). The organic solution was washed with satd. aqueous NaHCO₃ and brine, then dried over MgSO₄. Evaporation of solvent gave the crude material which was purified by a silica gel flash chromatography, eluting with 20% EtOAc in hexanes to afford (2S,3S,4aR,8S,8aR)-tert-butyl-8-formyl-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white solid (274 mg, 95%).

[00157] To a solution of the above material (274 mg, 0.71 mmol) in MeOH (10 mL) was added dimethyl(1-diazo-2-oxopropyl)phosphonate (279 mg, 1.45 mmol) followed by addition of K₂CO₃ (265 mg, 1.9 mmol). Gas evolution was observed and the reaction mixture became light yellow. The mixture was stirred overnight at room temperature, concentrated, and


30

diluted with EtOAc (30 mL). The organic solution was washed with satd. aqueous NaHCO₃ and brine then dried over MgSO₄. Evaporation of solvent gave the crude material which was purified by a silica gel flash chromatography, eluting with 20% EtOAc in hexanes to afford (2S,3S,4aR,8S,8aR)-tert-butyl 8-ethynyl-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (104 mg, 39%) as a white foam.

[00158] The above material (100 mg, 0.26 mmol) was dissolved in TFA/H₂O (9:1, 2 mL) and the mixture was stirred for 2 h at room temperature then evaporated to dryness. The crude material was purified by a silica gel flash chromatography, eluting with 5:10:85 NH₄OH:MeOH:DCM to afford (6R,7R,8S)-8-ethynyl-4-azaspiro[2.5]octane-6,7-diol (40 mg, 93%). ¹H NMR (500 MHz, *d*-MeOH) δ 3.43-3.36 (m, 2H), 3.05 (dd, *J* = 13, 4.5 Hz, 1H), 2.83 (d, *J* = 8.5 Hz, 1H), 2.52-2.48 (m, 1H), 2.36 (d, *J* = 2 Hz, 1H), 1.10-0.87 (m, 2H), 0.62-0.59 (m, 1H), 0.48-0.44 (m, 1H); MS *m/z* 168.10 (M+1, 100%).

Example 21

15 **(6R,7R,8S)-8-(prop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol**




[00159] To a solution (2S,3S,4aR,8S,8aR)-tert-butyl 8-ethynyl-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (107 mg, 0.28 mmol) in THF (2 mL) at -78 °C was added *n*-BuLi (1.6 M in hexanes, 0.2 mL, 0.34 mmol) and the resulting solution was stirred for 10 min at 0 °C. After addition of MeI (0.1 mL, 1.62 mmol), the reaction was stirred for 3 h at room temperature, then concentrated and diluted with EtOAc (20 mL). The organic phase was washed with satd. aqueous NaHCO₃ and brine then dried over MgSO₄. Evaporation of solvent gave the crude material which was purified by silica gel flash chromatography, eluting with 10% EtOAc in hexanes to afford (2S,3S,4aR,8S,8aR)-tert-butyl 2,3-dimethoxy-2,3-dimethyl-8-(prop-1-yn-1-yl)tetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (103 mg, 93%) as a white foam.

[00160] The above material (103 mg, 0.26 mmol) was dissolved in TFA/H₂O (9:1, 2 mL) and the mixture was stirred for 2 h at room temperature then evaporated to dryness. The crude material was purified by silica gel flash chromatography, eluting with 5:10:85

NH₄OH:MeOH:DCM to afford (6R,7R,8S)-8-(prop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol (32 mg, 70%) as a white foam. ¹H NMR (400 MHz, *d*-MeOH) δ 3.42-3.36 (m, 2H), 3.96 (dd, *J* = 12.8, 4.8 Hz, 1H), 2.77 (d, *J* = 10 Hz, 1H), 2.48 (dd, *J* = 10.4, 12.8 Hz, 1H), 1.76 (d, *J* = 2.4, 3H), 0.89-0.81 (m, 2H), 0.58-0.54 (m, 1H), 0.43-0.40 (m, 1H); MS *m/z* 181.11 (M+1, 100%).

Example 22

(6R,7R,8S)-8-(but-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol



[00161] At 0°C under N₂, to a mixture of PPh₃ (1.05 g, 4.01 mmol) and Zn dust (0.131 g, 2.00 mmol) in anhydrous DCM (30 mL) was added CBr₄ (0.663 g, 2.00 mmol). After the mixture was stirred at 0°C for 15 min and then at room temperature for 20 min, a solution of (2S,3S,4aR,8S,8aR)-tert-butyl-8-formyl-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (0.390 g, 1.01 mmol) in DCM (10 mL) was added. The reaction mixture was stirred at room temperature for 6 h, at which time completion was indicated by TLC. Hexane (50 mL) was added, and the resulting precipitate was filtered off. The filtrate was concentrated under reduced pressure, and the residue was purified on silica gel by automatic flash column chromatography (EtOAc/hexanes, 1:10 to 1:5), affording (2S,3S,4aR,8S,8aR)-tert-butyl 8-(2,2-dibromovinyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white solid (0.513 g, 98%). ¹H NMR (400 MHz, CDCl₃) δ 5.83 (d, *J* = 9.0 Hz, 1H), 4.09-4.01 (m, 1H), 3.74 (dd, *J* = 9.5, 10.3 Hz, 1H), 3.71-3.63 (m, 1H), 3.29 (s, 3H), 3.25 (s, 3H), 3.01-2.95 (m, 1H), 2.85-2.78 (m, 1H), 1.46 (s, 9H), 1.31 (s, 3H), 1.30 (s, 3H), 1.21-1.13 (m, 1H), 0.99-0.93 (m, 1H), 0.47-0.38 (m, 2H).


[00162] At -78°C under N₂, to a solution of the above material (0.130 g, 0.252 mmol) in anhydrous THF (6 mL) was added *n*-BuLi (1.6 M in hexanes, 0.47 mL, 0.75 mmol). After the mixture was stirred at -78°C for 1 h, EtI (0.32 g, 2.0 mmol) was added. The reaction mixture was brought to room temperature and stirred overnight. Saturated aqueous NH₄Cl (10 mL) was added, and the mixture was extracted with EtOAc (3 × 10 mL). The combined organic extract was dried over anhydrous Na₂SO₄. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash column

chromatography (EtOAc/hexanes, 1:10), affording (2S,3S,4aR,8S,8aR)-tert-butyl 8-(but-1-yn-1-yl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white foam (0.044 g, 43%). ¹H NMR (400 MHz, CDCl₃) δ 3.98 (s, br., 1H), 3.65 (dd, *J* = 9.5, 10.4 Hz, 1H), 3.60-3.57 (m, 1H), 3.31 (s, 3H),
 5 3.26 (s, 3H), 2.95-2.88 (m, 1H), 2.86-2.78 (m, 1H), 2.09 (dq, *J* = 2.1, 7.5 Hz, 2H), 1.43 (s, 9H), 1.32 (s, 3H), 1.31 (s, 3H), 1.05 (t, *J* = 7.5 Hz, 3H), 0.92-0.88 (m, 3H), 0.41-0.36 (m, 1H).

[00163] The above material (0.034 g, 0.083 mmol) was treated with TFA/H₂O (1.5 mL/0.15 mL) overnight. The solvent was removed, and the residue was neutralized with 1.0 M NH₃ in
 10 MeOH and subsequently purified on silica gel by flash column chromatography (1.0 M NH₃ in MeOH/DCM, 1:8), affording (6R,7R,8S)-8-(but-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol as a white solid (0.011 g, 70%). ¹H NMR (400 MHz, CD₃OD) δ 3.42-3.35 (m, 1H), 2.97 (dd, *J* = 4.8, 12.7 Hz, 1H), 2.80-2.74 (m, 1H), 2.48 (dd, *J* = 10.6, 12.7 Hz, 1H), 2.13 (dq, *J* = 2.2, 7.5 Hz, 2H), 1.09 (t, *J* = 7.5 Hz, 3H), 0.92-0.82 (m, 2H), 0.60-0.54 (m, 1H), 0.44 - 0.40
 15 (m, 1H); MS, *m/z* = 196.13 [M+H].

Example 23

(6R,7R,8S)-8-(pent-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol




[00164] At -78°C, under N₂, to a solution of ((4aR,8S,8aR)-tert-butyl 8-(2,2-dibromovinyl)-
 20 2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (0.140 g, 0.259 mmol) in anhydrous THF (5 mL) was added n-BuLi (1.6 M in hexanes, 0.50 mL, 0.80 mmol). After the mixture was stirred at -78°C for 2 h, CH₃CH₂CH₂I (0.52 g, 3.1 mmol) was added. The reaction mixture was brought to room temperature and stirred for 40 h. Saturated aqueous NH₄Cl (10 mL) was added, and
 25 the mixture was extracted with EtOAc (3 × 10 mL). The combined organic extract was dried over anhydrous Na₂SO₄. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by automatic flash column chromatography (EtOAc/hexanes, 1:15 to 1:8), affording (4aR,8S,8aR)-tert-butyl 2,3-dimethoxy-2,3-dimethyl-8-(pent-1-yn-1-yl)tetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-
 30 cyclopropane]-6(3H)-carboxylate as a clear oil (0.023 g, 21%). ¹H NMR (400 MHz, CDCl₃)

δ 3.99 (s, br., 1H), 3.66 (dd, $J = 9.6, 10.5$ Hz, 1H), 3.60-3.54 (m, 1H), 3.31 (s, 3H), 3.27 (s, 3H), 2.97-2.94 (m, 1H), 2.85-2.79 (m, 1H), 2.09-2.04 (m, 2H), 1.46-1.39 (m, 2H), 1.43 (s, 9H), 1.33 (s, 3H), 1.30 (s, 3H), 1.17 - 1.13 (m, 1H), 0.93 (t, $J = 7.3$ Hz, 3H), 0.90-0.86 (m, 2H), 0.43-0.39 (m, 1H).

- 5 [00165] The above material (0.023 g, 0.054 mmol) was treated with TFA/H₂O (1.5 mL/0.15 mL) overnight. The solvent was removed, and the residue was neutralized with 1.0 M NH₃ in MeOH and subsequently purified on silica gel by flash column chromatography (1.0 M NH₃ in MeOH/DCM, 1:7), affording (6R,7R,8S)-8-(pent-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol as a clear film (0.0083 g, 73%). ¹H NMR (400 MHz, CD₃OD) δ 3.42-3.36 (m, 1H),
 10 3.37-3.28 (m, 1H), 2.97 (dd, $J = 5.0, 12.7$ Hz, 1H), 2.80-2.76 (m, 1H), 2.48 (dd, $J = 10.6, 12.7$ Hz, 1H), 2.12 (dt, $J = 2.2, 7.1$ Hz, 2H), 1.48 (hexa, $J = 7.1$ Hz, 2H), 0.97 (t, $J = 7.1$ Hz, 3H), 0.87-0.82 (m, 2H), 0.57-0.54 (m, 1H), 0.45 - 0.41 (m, 1H); MS, $m/z = 210.15$ [M+H].

Example 24


(6R,7R,8S)-8-(3-hydroxyprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol



15

- [00166] (4aR,8S,8aR)-tert-butyl 8-(3-hydroxyprop-1-yn-1-yl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (0.033 g, 0.080 mmol) was treated with TFA/H₂O (1.5 mL/0.15 mL) overnight. The solvent was removed, and the residue was neutralized with 1.0 M NH₃ in MeOH and
 20 subsequently purified on silica gel by flash column chromatography (1.0 M NH₃ in MeOH/DCM, 1:4), affording (6R,7R,8S)-8-(3-hydroxyprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol as a white foam (0.014 g, 86%). ¹H NMR (400 MHz, CD₃OD) δ 4.14 (d, $J = 1.8$ Hz, 2H), 3.49-3.37 (m, 2H), 3.05 (dd, $J = 4.5, 12.7$ Hz, 1H), 2.90-2.86 (m, 1H), 2.57 (dd, $J = 10.2, 12.7$ Hz, 1H), 0.99-0.90 (m, 2H), 0.69-0.64 (m, 1H), 0.55 - 0.51 (m,
 25 1H); MS, $m/z = 198.11$ [M+H].

Example 25

(6R,7R,8S)-8-(3-fluoroprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol

- [00167] At -78°C , under N_2 , to a solution (4aR,8S,8aR)-tert-butyl 8-ethynyl-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (0.240 g, 0.629 mmol) in anhydrous THF (6 mL) was added n-BuLi (1.6 M in hexanes, 0.44 mL, 0.70 mmol). After the mixture was stirred at -78°C for 1 h, and then at 0°C for 30 min, at -78°C methyl chlorofomate (0.085 g, 0.90 mmol) was added. The reaction mixture was brought to 0°C and stirred at 0°C for 2 h. Saturated aqueous NaHCO_3 (10 mL) was added, and the mixture was extracted with EtOAc (2×10 mL). The combined organic extract was dried over anhydrous Na_2SO_4 . After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by automatic flash column chromatography (EtOAc/hexanes, 1:15 to 1:6), affording (4aR,8S,8aR)-tert-butyl 2,3-dimethoxy-8-(3-methoxy-3-oxoprop-1-yn-1-yl)-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white foam (0.170 g, 61%). ^1H NMR (400 MHz, CDCl_3) δ 4.01 (s, br., 1H), 3.81 (dd, $J = 9.5, 10.8$ Hz, 1H), 3.61-3.54 (m, 1H), 3.32 (s, 3H), 3.28 (s, 3H), 3.14-3.10 (m, 1H), 2.87-2.81 (m, 1H), 1.46 (s, 9H), 1.33 (s, 3H), 1.31 (s, 3H), 1.35-1.30 (m, 1H), 1.27-1.21 (m, 1H), 0.90-0.87 (m, 1H), 0.54-0.48 (m, 1H).
- [00168] At -78°C , under N_2 , to a solution of the above material (0.170 g, 0.386 mmol) in anhydrous THF (5 mL) was added DIBAL-H (1.0 M in THF, 1.2 mL, 1.2 mmol). After the mixture was stirred at 0°C for 2 h, saturated aqueous NaHCO_3 (10 mL) was added and the mixture was extracted with EtOAc (2×10 mL). The combined organic extract was dried over anhydrous Na_2SO_4 . After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by automatic flash column chromatography (EtOAc/hexanes, 1:4 to 1:2), affording (4aR,8S,8aR)-tert-butyl 8-(3-hydroxyprop-1-yn-1-yl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white foam (0.145 g, 91%). ^1H NMR (400 MHz, CDCl_3) δ 4.18 (d, $J = 2.3$ Hz, 2H), 3.98 (s, br., 1H), 3.70 (dd, $J = 9.5, 10.7$ Hz, 1H), 3.59-3.52 (m, 1H), 3.30 (s, 3H), 3.26 (s, 3H), 3.03-3.00 (m, 1H), 2.86-2.79 (m, 1H), 1.43 (s, 9H), 1.32


(s, 3H), 1.29 (s, 3H), 1.30-1.26 (m, 1H), 1.20-1.15 (m, 1H), 0.89-0.84 (m, 1H), 0.46-0.40 (m, 1H).

[00169] At -78°C, under N₂, to a solution of the above material (0.120 g, 0.290 mmol) in anhydrous DCM (3 mL) was added DAST (0.43 g, 2.7 mmol). After the mixture was stirred at room temperature overnight, at -78°C saturated aqueous NaHCO₃ (5 mL) was added and the mixture was extracted with DCM (2 × 5 mL). The combined organic extract was dried over anhydrous Na₂SO₄. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by automatic flash column chromatography (EtOAc/hexanes, 1:12 to 1:5), affording (4aR,8S,8aR)-tert-butyl 8-(3-fluoroprop-1-yn-1-yl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white foam (0.112 g, 93%). ¹H NMR (400 MHz, CDCl₃) δ 4.89 (dd, *J* = 1.9, 47.4 Hz, 2H), 4.04 (s, br., 1H), 3.75 (dd, *J* = 9.9, 11.2 Hz, 1H), 3.61-3.55 (m, 1H), 3.31 (s, 3H), 3.28 (s, 3H), 3.10 (s, br., 1H), 2.87-2.81 (m, 1H), 1.44 (s, 9H), 1.34 (s, 3H), 1.31 (s, 3H), 1.32-1.25 (m, 1H), 1.23-1.18 (m, 1H), 0.92-0.86 (m, 1H), 0.49-0.43 (m, 1H).

[00170] The above material (0.112 g, 0.271 mmol) was treated with TFA/H₂O (2 mL/0.2 mL) overnight. The solvent was removed, and the residue was neutralized with 1.0 M NH₃ in MeOH and subsequently purified on silica gel by flash column chromatography (1.0 M NH₃ in MeOH/DCM, 1:7), affording (6R,7R,8S)-8-(3-fluoroprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol as a white foam (0.044 g, 81%). ¹H NMR (400 MHz, CD₃OD) δ 4.93 (dd, *J* = 1.9, 47.5 Hz, 2H), 3.41-3.37 (m, 2H), 3.00-2.95 (m, 1H), 2.93-2.88 (m, 1H), 2.52-2.46 (m, 1H), 0.90-0.81 (m, 2H), 0.64-0.59 (m, 1H), 0.48 - 0.44 (m, 1H); MS, *m/z* = 200.11 [M+H].

Example 26

(6R,7R,8S)-8-(3,3-difluoroprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol



[00171] At -78°C, under N₂, to a solution ((4aR,8S,8aR)-tert-butyl 8-(2,2-dibromovinyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (0.160 g, 0.296 mmol) in anhydrous THF (6 mL) was added n-BuLi (1.6

M in hexanes, 0.75 mL, 1.2 mmol). After the mixture was stirred at -78°C for 1.5 h, anhydrous DMF (0.2 mL) was added. The reaction mixture was brought to 0°C and stirred at 0°C for 2 h. Saturated aqueous NaHCO_3 (5 mL) was added, and the mixture was extracted with EtOAc (2×5 mL). The combined organic extract was dried over anhydrous Na_2SO_4 .


5 After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by automatic flash column chromatography (EtOAc/hexanes, 1:6 to 1:4), affording (4aR,8S,8aR)-tert-butyl 2,3-dimethoxy-2,3-dimethyl-8-(3-oxoprop-1-yn-1-yl)tetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white foam (0.075 g, 62%). ^1H NMR (400 MHz, CDCl_3) δ 9.15 (d, $J = 0.6$ Hz, 1H), 4.01 (s, br., 1H), 3.83 (dd, $J = 9.5, 10.8$ Hz, 1H), 3.63-3.56 (m, 1H), 3.31 (s, 3H), 3.29 (s, 3H), 3.29-3.23 (m, 1H), 2.89-2.83 (m, 1H), 1.44 (s, 9H), 1.34 (s, 3H), 1.31 (s, 3H), 1.33-1.22 (m, 2H), 0.90-0.85 (m, 1H), 0.57-0.52 (m, 1H).

[00172] At -78°C , under N_2 , to a solution of the above material (0.065 g, 0.16 mmol) in anhydrous DCM (3 mL) was added DAST (0.43 g, 2.7 mmol). After the mixture was stirred at room temperature for 3 days, at -78°C saturated aqueous NaHCO_3 (5 mL) was added and the mixture was extracted with DCM (2×5 mL). The combined organic extract was dried over anhydrous Na_2SO_4 . After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by automatic flash column chromatography (EtOAc/hexanes, 1:12 to 1:5), affording (4aR,8S,8aR)-tert-butyl 8-(3,3-difluoroprop-1-yn-1-yl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white foam (0.069 g, 100%). ^1H NMR (400 MHz, CDCl_3) δ 6.11 (dt, $J = 1.2, 55.0$ Hz, 1H), 4.00 (s, br., 1H), 3.78 (dd, $J = 9.5, 10.8$ Hz, 1H), 3.60-3.54 (m, 1H), 3.30 (s, 3H), 3.27 (s, 3H), 3.10 (s, br., 1H), 2.86-2.80 (m, 1H), 1.44 (s, 9H), 1.33 (s, 3H), 1.30 (s, 3H), 1.30-1.20 (m, 2H), 0.92-0.85 (m, 1H), 0.53-0.47 (m, 1H).


25 [00173] The above material (0.069 g, 0.16 mmol) was treated with TFA/ H_2O (1.5 mL/0.15 mL) overnight. The solvent was removed, and the residue was neutralized with 1.0 M NH_3 in MeOH and subsequently purified on silica gel by flash column chromatography (1.0 M NH_3 in MeOH/DCM, 1:7), affording (6R,7R,8S)-8-(3,3-difluoroprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol as a white foam (0.028 g, 81%). ^1H NMR (400 MHz, CD_3OD) δ 6.33 (dt, $J = 1.2, 54.8$ Hz, 1H), 3.45-3.37 (m, 2H), 3.01-2.94 (m, 2H), 2.53-2.47 (m, 1H), 0.89-0.79 (m, 2H), 0.69-0.64 (m, 1H), 0.54 - 0.49 (m, 1H); MS, $m/z = 218.10$ [M+H].

30

Example 27

(6R,7R,8S)-8-(4-fluorobut-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol

- [00174] At -78°C , under N_2 , to a solution of ((4aR,8S,8aR)-tert-butyl 8-(2,2-dibromovinyl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate (0.130 g, 0.240 mmol) in anhydrous THF (5 mL) was added n-BuLi (1.6 M in hexanes, 0.50 mL, 0.80 mmol). After the mixture was stirred at -78°C for 1.5 h, $\text{FCH}_2\text{CH}_2\text{I}$ (0.261 g, 1.50 mmol) was added. The reaction mixture was brought to room temperature and stirred overnight. Saturated aqueous NH_4Cl (10 mL) was added, and the mixture was extracted with EtOAc (3×10 mL). The combined organic extract was dried over anhydrous Na_2SO_4 . After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by automatic flash column chromatography (EtOAc/hexanes, 1:15 to 1:8), affording (4aR,8S,8aR)-tert-butyl 8-(4-fluorobut-1-yn-1-yl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as a white foam (0.0082 g, 8%). ^1H NMR (400 MHz, CDCl_3) δ 4.40 (td, $J = 6.6, 46.7$ Hz, 2H), 3.98 (s, br., 1H), 3.67 (dd, $J = 9.6, 10.6$ Hz, 1H), 3.59-3.53 (m, 1H), 3.31 (s, 3H), 3.27 (s, 3H), 2.97-2.93 (m, 1H), 2.86-2.80 (m, 1H), 2.52 (dtd, $J = 2.1, 6.6, 19.7$ Hz, 2H), 1.44 (s, 9H), 1.33 (s, 3H), 1.30 (s, 3H), 1.31-1.27 (m, 1H), 1.23-1.14 (m, 1H), 0.89-0.85 (m, 1H), 0.45-0.41 (m, 1H).
- [00175] The above material (0.020 g, 0.047 mmol) was treated with TFA/ H_2O (1.5 mL/0.15 mL) overnight. The solvent was removed, and the residue was neutralized with 1.0 M NH_3 in MeOH and subsequently purified on silica gel by flash column chromatography (1.0 M NH_3 in MeOH/DCM, 1:7), affording (6R,7R,8S)-8-(4-fluorobut-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol as a clear film (0.0044 g, 44%). ^1H NMR (400 MHz, CD_3OD) δ 4.42 (td, $J = 6.4, 46.9$ Hz, 2H), 3.41-3.29 (m, 2H), 2.96 (dd, $J = 4.8, 12.7$ Hz, 1H), 2.80-2.78 (m, 1H), 2.54 (dtd, $J = 2.5, 6.4, 21.2$ Hz, 2H), 2.47 (dd, $J = 10.4, 12.7$ Hz, 1H), 0.91-0.82 (m, 2H), 0.58-0.54 (m, 1H), 0.44 - 0.39 (m, 1H); MS, $m/z = 214.12$ [M+H].

Example 28**(6R,7R,8S)-8-(4,4-difluorobut-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol**

[00176] Under N₂, to a solution (4aR,8S,8aR)-tert-butyl 8-ethynyl-2,3-dimethoxy-2,3-
5 dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-
carboxylate (0.100 g, 0.262 mmol) in anhydrous CH₃CN (5 mL) was added tert-butyl
diazoacetate (0.075 g, 0.52 mmol), and CuI (0.015 g, 0.077 mmol). After the mixture was
stirred at room temperature for 24 h, the solvent was evaporated under reduced pressure, and
the residue was purified on silica gel by automatic flash column chromatography
10 (EtOAc/hexanes, 1:10 to 1:4), affording (4aR,8S,8aR)-tert-butyl 8-(4-(tert-butoxy)-4-oxobut-
1-yn-1-yl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-
cyclopropane]-6(3H)-carboxylate as an oil (0.045 g, 35%). Its ¹H NMR is complex due to
the existence of two stable rotamers in CDCl₃ at room temperature.

[00177] At 0°C, under N₂, to a solution of the above material (0.045 g, 0.091 mmol) in
15 anhydrous THF (5 mL) was added DIBAL-H (1.0 M in THF, 0.30 mL, 0.30 mmol). After
the mixture was stirred at 0°C for 2 h, saturated aqueous NaHCO₃ (10 mL) was added and the
mixture was extracted with EtOAc (2 × 10 mL). The combined organic extract was dried
over anhydrous Na₂SO₄. After filtration the solvent was evaporated under reduced pressure,
and the residue was purified on silica gel by automatic flash column chromatography
20 (EtOAc/hexanes, 1:4 to 1:2), affording (4aR,8S,8aR)-tert-butyl 8-(4-hydroxybut-1-yn-1-yl)-
2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-
cyclopropane]-6(3H)-carboxylate as an oil (0.026 g, 67%). ¹H NMR (400 MHz, CDCl₃) δ
4.00 (s, br., 1H), 3.69 (dd, *J* = 9.6, 11.0 Hz, 1H), 3.62 (dt, *J* = 1.3, 6.1 Hz, 2H), 3.59-3.53 (m,
1H), 3.31 (s, 3H), 3.27 (s, 3H), 3.02 (s, br., 1H), 2.87-2.81 (m, 1H), 2.37 (dt, *J* = 2.2, 6.1 Hz,
25 2H), 1.44 (s, 9H), 1.34 (s, 3H), 1.31 (s, 3H), 1.31-1.25 (m, 1H), 1.23-1.15 (m, 1H), 0.89-0.82
(m, 1H), 0.46-0.40 (m, 1H).

[00178] To a solution of the above material (0.026 g, 0.061 mmol) in DCM (3 mL) was
added DMP (0.075 g, 0.18 mmol), and the mixture was stirred at room temperature for 1 h.
The solvent was removed and the residue was diluted with saturated aqueous NaHCO₃ (5
30 mL), and then extracted with EtOAc (3 × 5 mL). The combined organic extract was dried

over anhydrous Na₂SO₄. After filtration the solvent was evaporated under reduced pressure, and the residue, (4aR,8S,8aR)-tert-butyl 2,3-dimethoxy-2,3-dimethyl-8-(4-oxobut-1-yn-1-yl)tetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate, was dissolved in anhydrous DCM (3 mL). At -78°C, under N₂, to the solution was added
5 DAST (0.43 g, 2.7 mmol). After the mixture was stirred at room temperature for 3 days, at -78°C saturated aqueous NaHCO₃ (5 mL) was added and the mixture was extracted with DCM (2 × 5 mL). The combined organic extract was dried over anhydrous Na₂SO₄. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by automatic flash column chromatography (EtOAc/hexanes, 1:12 to 1:5), affording
10 (4aR,8S,8aR)-tert-butyl 8-(4,4-difluorobut-1-yn-1-yl)-2,3-dimethoxy-2,3-dimethyltetrahydro-2H-spiro[[1,4]dioxino[2,3-c]pyridine-7,1'-cyclopropane]-6(3H)-carboxylate as an oil (0.015 g, 55% in 2 steps). ¹H NMR (400 MHz, CDCl₃) δ 5.77 (tt, *J* = 4.4, 56.3 Hz, 1H), 3.99 (s, br., 1H), 3.70 (dd, *J* = 9.5, 10.7 Hz, 1H), 3.59-3.52 (m, 1H), 3.30 (s, 3H), 3.27 (s, 3H), 2.99 (s, br., 1H), 2.86-2.80 (m, 1H), 2.68 (ddt, *J* = 2.2, 4.4, 15.5 Hz, 2H), 1.44 (s, 9H), 1.33 (s, 3H),
15 1.30 (s, 3H), 1.30-1.24 (m, 1H), 1.23-1.15 (m, 1H), 0.90-0.85 (m, 1H), 0.460-0.42 (m, 1H).
[00179] The above material (0.015 g, 0.034 mmol) was treated with TFA/H₂O (1 mL/0.1 mL) overnight. The solvent was removed, and the residue was neutralized with 1.0 M NH₃ in MeOH and subsequently purified on silica gel by flash column chromatography (1.0 M NH₃ in MeOH/DCM, 1:7), affording (6R,7R,8S)-8-(4,4-difluorobut-1-yn-1-yl)-4-
20 azaspiro[2.5]octane-6,7-diol as a white foam (0.0060 g, 77%). ¹H NMR (400 MHz, CD₃OD) δ 5.91 (tt, *J* = 4.2, 56.4 Hz, 1H), 3.42-3.34 (m, 2H), 2.97 (dd, *J* = 4.2, 12.7 Hz, 1H), 2.83-2.81 (m, 1H), 2.74 (ddt, *J* = 2.2, 4.2, 16.1 Hz, 2H), 2.49 (dd, *J* = 10.4, 12.7 Hz, 1H), 0.92-0.83 (m, 2H), 0.61-0.57 (m, 1H), 0.47 - 0.42 (m, 1H); MS, *m/z* = 232.12 [M+H].
[00180] Examples 29 to 76, as indicated in Table 1, are synthesized according to procedures
25 analogous to the schemes and examples outlined herein.

Biological Activity

Assay for determination of Ki values for inhibition of GCCase activity

[00181] Various concentrations of test compounds were prepared in DMSO and then diluted
30 into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium taurodexoycholate, pH 7.0. GCCase enzyme (Cerezyme®, recombinant human GCCase obtained from R&D Systems) was diluted in the same buffer to 0.143 nM. The reaction solution consisted of 25 μL of 6

mM 4-methylumbelliferone- β -D glucopyranoside in 10% DMSO in the same buffer, 12.5 μ L of enzyme and 12.5 μ L of various concentrations of test compound diluted in buffer. The final concentrations in the reaction were 0.036 nM GCase, 3 mM 4-methylumbelliferone- β -D glucopyranoside, and various concentrations of inhibitor. The reaction was initiated by
5 addition of enzyme and allowed to proceed for 20 min at 37°C to assess GCase activity. Reactions were stopped by the addition of an equal volume (50 μ L) of 0.5 M NaOH, 0.3 M glycine, pH 10.5. Fluorescence was measured on a Biotek Synergy H4 plate reader using a setting of 10 measurements per data point at wavelengths of 365 nm for excitation and 450 nm for emission. Incubations without added enzyme or added inhibitors were used to define
10 no enzyme activity and maximal enzyme activity, respectively. IC₅₀ values were determined by fitting the data to a log[inhibitor concentration] versus response curve using GraphPad Prism. IC₅₀ values were calculated as the concentration of inhibitor required to inhibit GCase activity by 50%. Ki values were determined from the IC₅₀ values by employing the Cheng-Prusoff equation using a GCase Km of 7.9 mM for 4-methylumbelliferone- β -D
15 glucopyranoside at pH 7.0.

[00182] The compounds of the invention tested exhibit Ki values for inhibition of GCase in the range 0.1 nM - 50 μ M.

Assay for determination of apparent permeability (P_{app})

[00183] Bi-directional transport is evaluated in LLC-PK1 cells in order to determine
20 apparent permeability (P_{app}). LLC-PK1 cells can form a tight monolayer and therefore can be used to assess vectorial transport of compounds from basolateral to apical (B→A) and from apical to basolateral (A → B).

[00184] To determine P_{app}, LLC-PK1 cells are cultured in 96-well transwell culture plates (Millipore). Solutions containing the test compounds (1 μ M) are prepared in Hank's
25 Balanced Salt Solution with 10 mM HEPES. Substrate solution (150 μ L) is added to either the apical (A) or the basolateral (B) compartment of the culture plate, and buffer (150 μ L) is added to the compartment opposite to that containing the compound. At t = 3 h, 50 μ L samples are removed from both sides of monolayers dosed with test compound and placed in
30 96 well plates, scintillant (200 μ L) or internal standard (100 μ L labetolol 1 μ M) is added to the samples and concentration is determined by liquid scintillation counting in a MicroBeta Wallac Trilux scintillation counter (Perkin Elmer Life Sciences, Boston, MA) or by LCMS/MS (Applied Biosystems SCIEX API 5000 triple quadruple mass spectrometer).

[³H]Verapamil (1 μM) is used as the positive control. The experiment is performed in triplicate.

[00185] The apparent permeability, P_{app} , is calculated by the following formula for samples taken at $t = 3$ h:

$$P_{app} = \frac{\text{Volume of Receptor Chamber (mL)}}{[\text{Area of membrane (cm}^2\text{)}][\text{Initial Concentration } (\mu\text{M)}]} \times \frac{\Delta \text{ in Concentration } (\mu\text{M})}{\Delta \text{ in Time (s)}}$$




Where: Volume of Receptor Chamber is 0.15 mL; Area of membrane is 0.11 cm²; the Initial Concentration is the sum of the concentration measured in the donor plus concentration measured in receiver compartments at $t = 3$ h; Δ in Concentration is concentration in the receiver compartment at 3 h; and Δ in Time is the incubation time ($3 \times 60 \times 60 = 10800$ s).











P_{app} is expressed as 10⁻⁶ cm/s. The P_{app} (LLC-PK1 cells) are the average of the P_{app} for transport from A to B and P_{app} for transport from B to A at $t = 3$ h:











$$P_{app}(\text{LLC - PK1 Cells}) = \frac{P_{app}(A \rightarrow B) + P_{app}(B \rightarrow A)}{2}$$

[00186] Representative data from the binding assay described above are shown in the following table. For comparison, the first two table entries show data for literature compounds (3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol and (3R,4R,5R)-5-(hydroxymethyl)-6,6-dipropylpiperidine-3,4-diol.

Table 2

Example	Structure	GCCase IC ₅₀ (nM)	GCCase Ki (nM)
N/A		8.2	1.7
N/A		ND	1400 ^a
N/A		3,440	ND

Example	Structure	GCase IC ₅₀ (nM)	GCase Ki (nM)
1		3.7	2.6
2		13	7.0
3		6.2	2.1
4		6.5	8.0
5		7.4	ND
6		7.5	ND
7		32	ND
8		75	ND
9		507	ND
10		264	ND

Example	Structure	GCase IC ₅₀ (nM)	GCase Ki (nM)
11		462	ND
12		6.3	ND
13		15	ND
14		27	ND
15		56	ND
16		6.8	7.6
17		36	ND
18		20	ND
19		75	ND
20		13	7.9

Example	Structure	GCase IC ₅₀ (nM)	GCase Ki (nM)
21		9.7	6.7
22		2.4	ND
23		6.7	ND
24		17	ND
25		16	15
26		22	17
27		2.5	ND
28		11	ND

^aFrom Hill et al. *ChemBioChem* **2011**, 12, 2151, Ki measured at pH 7.0.

[00187] The present invention has been described with regard to one or more embodiments.

However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in


5 the claims.

REFERENCES

1. Al-Mansoori, K.M. et al. *Current Alzheimer Research* **2013**, *10*, 559-568.
2. Sardi, S. et al. *Proceedings of the National Academy of Sciences* **2013**, *110*, 3537-3542.
- 5 3. Sardi, S. et al. *Neurodegenerative Diseases* **2012**, *10*, 195-202.
4. Sardi, S. et al. *Proceedings of the National Academy of Sciences* **2011**, *108*, 12101-12106.
- 10 5. Kong, B. et al. *European Review for Medical and Pharmaceutical Sciences* **2013**, *17*, 143-151.
6. Clark, S. et al. "Improved Pharmacological Chaperones for the Treatment of Neuronopathic Gaucher and Parkinson's Disease," Lysosomal Disease Network, World Symposium, **2011**.
7. Chesselet, M.-F. et al. *Neurotherapeutics* **2012**, *9*, 677-678.
- 15 8. Grabowski, G. A. *Lancet* **2008**, *372*, 1263-1271.
9. Boyd, R.E. et al. *Journal of Medicinal Chemistry* **2013**, *56*, 2705-2725.
10. Parenti, G. *EMBO Molecular Medicine* **2009**, *1*, 268-279.
11. Fan, J.Q. *Trends in Pharmaceutical Sciences* **2003**, *24*, 355-360.
12. Alberio, T. et al. *FEBS Journal* **2012**, *279*, 1146-1155.
- 20 13. Dawson, T.M. et al. *Neuron* **2010**, *66*, 646-661.
14. Khanna, R. et al. *FEBS Journal* **2010**, *277*, 1618-1638.
15. Panicker, L.M. *Proceedings of the National Academy of Sciences* **2012**, *109*, 18054-18059.
- 25 16. Farfel-Becker, T. et al. *Disease Models & Mechanisms* **2011**, *4*, 746-752.

WHAT IS CLAIMED IS:

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)

5 wherein

R^1 is OH and R^2 is H or methyl; or R^1 is F and R^2 is H or F; or R^1 is H and R^2 is F;

R^3 is: C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, C₃₋₈ cycloalkyl, C₄₋₁₀ cycloalkylalkyl, C₂₋₁₀ alkoxyalkyl, C₇₋₁₅ arylalkyl, or C₂₋₁₅ heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH₃, and/or OH; or R^3 is CN, CO₂H, C(O)NHCH₃, or C(O)NH(cyclopropyl); and

R^4 is: H or C₁₋₁₀ alkyl, said C₁₋₁₀ alkyl optionally substituted from one up to the maximum number of substituents with F and/or OH.

2. The compound of claim 1 wherein:

R^1 is OH and R^2 is H;

15 R^3 is: methyl, hydroxymethyl, fluoromethyl, difluoromethyl, chloromethyl, methoxymethyl, methoxy, CN, CO₂H, C(O)NHCH₃, C(O)NH(cyclopropyl); ethyl, propyl, 2-fluoroethyl, 2,2-difluoroethyl, vinyl, (Z)-2-fluorovinyl, (E)-2-fluorovinyl, 2,2-difluorovinyl, ethynyl, prop-1-yn-1-yl, but-1-yn-1-yl, pent-1-yn-1-yl, 3-hydroxyprop-1-yn-1-yl, 3-fluoroprop-1-yn-1-yl, 3,3-difluoroprop-1-yn-1-yl, or 4,4-difluorobut-1-yn-1-yl; and

20 R^4 is H.

3. The compound of claim 1 wherein the compound is:

(6R,7R,8S)-8-methyl-4-azaspiro[2.5]octane-6,7-diol;

(6R,7R,8R)-8-(hydroxymethyl)-4-azaspiro[2.5]octane-6,7-diol;


(6R,7R,8S)-8-(fluoromethyl)-4-azaspiro[2.5]octane-6,7-diol;

25 (6R,7R,8S)-8-(difluoromethyl)-4-azaspiro[2.5]octane-6,7-diol;

(6R,7R,8S)-8-(chloromethyl)-4-azaspiro[2.5]octane-6,7-diol;

- (6R,7R,8R)-8-(methoxymethyl)-4-azaspiro[2.5]octane-6,7-diol;
(6R,7S,8S)-8-methoxy-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8R)-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carbonitrile;
(6R,7R,8S)-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carboxylic acid;
5 (6R,7R,8S)-6,7-dihydroxy-N-methyl-4-azaspiro[2.5]octane-8-carboxamide;
(6R,7R,8S)-N-cyclopropyl-6,7-dihydroxy-4-azaspiro[2.5]octane-8-carboxamide;
(6R,7R,8S)-8-ethyl-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-propyl-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-(2-fluoroethyl)-4-azaspiro[2.5]octane-6,7-diol;
10 (6R,7R,8S)-8-(2,2-difluoroethyl)-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-vinyl-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-((Z)-2-fluorovinyl)-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-((E)-2-fluorovinyl)-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-(2,2-difluorovinyl)-4-azaspiro[2.5]octane-6,7-diol;
15 (6R,7R,8S)-8-ethynyl-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-(prop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-(but-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-(pent-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-(3-hydroxyprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol;
20 (6R,7R,8S)-8-(3-fluoroprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-(3,3-difluoroprop-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol;
(6R,7R,8S)-8-(4-fluorobut-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol; or
(6R,7R,8S)-8-(4,4-difluorobut-1-yn-1-yl)-4-azaspiro[2.5]octane-6,7-diol;
or a pharmaceutically acceptable salt of any of the foregoing compounds.
- 25 4. The compound of claim 1 wherein the compound is a prodrug.
5. The compound of any one of claims 1 to 4 wherein the compound inhibits a β -glucocerebrosidase (GCase).
6. The compound of any one of claims 1 to 5 wherein the compound binds a GCase.
7. The compound of any one of claims 1 to 6 wherein the compound acts as a modulator
30 for a GCase.
8. The compound of any one of claims 1 to 7 wherein the compound increases protein levels and/or enzyme activity levels of a GCase.

9. The compound of claim 8 wherein the GCCase is a mammalian GCCase.
10. A pharmaceutical composition comprising the compound of any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.
- 5 11. A method of modulating a GCCase in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)


10 wherein

R^1 is OH and R^2 is H or methyl; or R^1 is F and R^2 is H or F; or R^1 is H and R^2 is F;

R^3 is: C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{3-8} cycloalkyl, C_{4-10} cycloalkylalkyl, C_{2-10} alkoxyalkyl, C_{7-15} arylalkyl, or C_{2-15} heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH_3 , and/or OH; or R^3 is CN, CO_2H , $C(O)NHCH_3$, or $C(O)NH(\text{cyclopropyl})$; and

R^4 is: H or C_{1-10} alkyl, said C_{1-10} alkyl optionally substituted from one up to the maximum number of substituents with F and/or OH.

12. A method of elevating the level of GCCase protein and/or GCCase enzyme activity in a subject in need thereof, the method comprising administering to the subject an effective
- 20 amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)


wherein

R^1 is OH and R^2 is H or methyl; or R^1 is F and R^2 is H or F; or R^1 is H and R^2 is F;

R^3 is: C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{3-8} cycloalkyl, C_{4-10} cycloalkylalkyl, C_{2-10} alkoxyalkyl, C_{7-15} arylalkyl, or C_{2-15} heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH_3 , and/or OH; or R^3 is CN, CO_2H , $C(O)NHCH_3$, or $C(O)NH(\text{cyclopropyl})$; and

R^4 is: H or C_{1-10} alkyl, said C_{1-10} alkyl optionally substituted from one up to the maximum number of substituents with F and/or OH.

13. A method of treating a condition that is modulated by a GCase, in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)


wherein

15 R^1 is OH and R^2 is H or methyl; or R^1 is F and R^2 is H or F; or R^1 is H and R^2 is F;

R^3 is: C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{3-8} cycloalkyl, C_{4-10} cycloalkylalkyl, C_{2-10} alkoxyalkyl, C_{7-15} arylalkyl, or C_{2-15} heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH_3 , and/or OH; or R^3 is CN, CO_2H , $C(O)NHCH_3$, or $C(O)NH(\text{cyclopropyl})$; and

20 R^4 is: H or C_{1-10} alkyl, said C_{1-10} alkyl optionally substituted from one up to the maximum number of substituents with F and/or OH.

14. A method of treating a condition selected from a neurodegenerative disease, a synucleopathy, and a lysosomal storage disease, in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein

R^1 is OH and R^2 is H or methyl; or R^1 is F and R^2 is H or F; or R^1 is H and R^2 is F;


5 R^3 is: C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, C_{3-8} cycloalkyl, C_{4-10} cycloalkylalkyl, C_{2-10} alkoxyalkyl, C_{7-15} arylalkyl, or C_{2-15} heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH_3 , and/or OH; or R^3 is CN, CO_2H , $C(O)NHCH_3$, or $C(O)NH(\text{cyclopropyl})$; and

10 R^4 is : H or C_{1-10} alkyl, said C_{1-10} alkyl optionally substituted from one up to the maximum number of substituents with F and/or OH.

15 The method of claim 13 or 14 wherein the condition is Parkinson's disease, Dementia with Lewy bodies, Multiple system atrophy, Pick's disease (PiD), Corticobasal degeneration (CBD), Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Amyotrophic lateral sclerosis with cognitive impairment (ALSci), Argyrophilic grain dementia, Bluit disease, Dementia pugilistica, Diffuse neurofibrillary tangles with calcification, Down's syndrome, Familial British dementia, Familial Danish dementia, Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Gerstmann-Straussler-Scheinker disease, Guadeloupean parkinsonism, Hallevorden-Spatz disease (neurodegeneration with brain iron accumulation type 1), Myotonic dystrophy, Multi-infarct dementia, Niemann-Pick disease (type C), Pallido-ponto-nigral degeneration, Parkinsonism-dementia complex of Guam, Post-encephalitic parkinsonism (PEP), Prion diseases (including Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (vCJD), Fatal Familial Insomnia, and Kuru), Progressive supercortical gliosis, Progressive supranuclear palsy (PSP), Richardson's syndrome, Subacute sclerosing panencephalitis, Tangle-only dementia, Huntington's disease, Schizophrenia, Mild Cognitive Impairment (MCI), Neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, and diabetic neuropathy), or Glaucoma.

20
25

16. The method of claim 13 or 14 wherein the condition is Parkinson's disease.
17. The method of claim 13 or 14 wherein the condition is Gaucher's disease.
18. The method of any one of claims 11 to 17 wherein the compound is one or more of the compounds described in Table 1.
- 5 19. The method of any one of claims 11 to 18 wherein said administering increases the level of GCCase protein and/or enzyme activity in the subject.
20. The method of any one of claims 11 to 19 wherein the subject is a human.
21. Use of a compound of an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:



10

(I)

wherein

R¹ is OH and R² is H or methyl; or R¹ is F and R² is H or F; or R¹ is H and R² is F;

- 15 R³ is: C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, C₃₋₈ cycloalkyl, C₄₋₁₀ cycloalkylalkyl, C₂₋₁₀ alkoxyalkyl, C₇₋₁₅ arylalkyl, or C₂₋₁₅ heteroarylalkyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, CH₃, and/or OH; or R³ is CN, CO₂H, C(O)NHCH₃, or C(O)NH(cyclopropyl); and

R⁴ is: H or C₁₋₁₀ alkyl, said C₁₋₁₀ alkyl optionally substituted from one up to the maximum number of substituents with F and/or OH, in the preparation of a medicament.

- 20 22. The use of claim 21 wherein said medicament is for modulating a GCCase, for increasing the level of GCCase protein and/or enzyme activity, for treating a condition modulated by a GCCase, or for treating a neurodegenerative disease, or a lysosomal storage disease.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA2014/051252

A. CLASSIFICATION OF SUBJECT MATTER
 IPC: **C07D 221/20** (2006.01), **A61K 31/438** (2006.01), **A61P 25/00** (2006.01), **A61P 25/16** (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC: C07D 221/20 (2006.01), A61K 31/438 (2006.01), A61P 25/00 (2006.01), A61P 25/16 (2006.01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)
 CAplus, Questel-Orbit, Canadian Patent Database, Scopus

Glucocerebrosidase, inhibit, chaperone, synucleinopathy, Parkinson's disease, Gaucher's disease

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO2005046612A2 (AMICUS THERAPEUTICS INC) 26 May 2005 (26-05-2005) fig. 2, compounds 11-16; p.3, 1.20 to p.4, 1.5; example 3, p.56, 1.21- p.57, 1.2; example 4, p.57-58; table 1, p.57.	1-22
A	WO2011049736A1 (AMMICUS THERAPEUTICS INC) 28 April 2011 (28-04-2011) table 2A, p.65; table 2B, p.67; p.6-13; p.8, 12.	1-22
A	WO2013075227A1 (THE HOSPITAL FOR SICK CHILDREN) 30 May 2013 p.37, 1. 12 to p.39, 1.3; table 2, p.39-40; compounds 3, 9, table 2; compounds 10-25, table 2.	1-22

Further documents are listed in the continuation of Box C.

See patent family annex.

* "A" "E" "L" "O" "P"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier application or patent but published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"T" "X" "Y" "&"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
--------------------------------------	--	--------------------------	--

Date of the actual completion of the international search
02 March 2015 (02-03-2015)

Date of mailing of the international search report
09 March 2015 (09-03-2015)

Name and mailing address of the ISA/CA
 Canadian Intellectual Property Office
 Place du Portage I, C114 - 1st Floor, Box PCT
 50 Victoria Street
 Gatineau, Quebec K1A 0C9
 Facsimile No.: 001-819-953-2476

Authorized officer

Yong-Huang Chen (819) 956-4113

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.: 11-21
because they relate to subject matter not required to be searched by this Authority, namely:
Claim 11-21 are directed to a method for treatment of the human or animal body by surgery or therapy, which the International Searching Authority is not required to search under Rule 39.1(iv) of the PCT. However, this Authority has carried out a search based on the alleged effect or purpose/use of the product defined in claims 1-10.
2. Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CA2014/051252

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date		
WO2005046612A2	26 May 2005 (26-05-2005)	WO2005046612A2	26 May 2005 (26-05-2005)		
		WO2005046612A3	14 July 2005 (14-07-2005)		
		AU2004289327A1	26 May 2005 (26-05-2005)		
		AU2004289328A1	26 May 2005 (26-05-2005)		
		AU2004289328B2	19 May 2011 (19-05-2011)		
		BRPI0416216A	26 December 2006 (26-12-2006)		
		BRPI0416217A	02 January 2007 (02-01-2007)		
		CA2545433A1	26 May 2005 (26-05-2005)		
		CA2545435A1	26 May 2005 (26-05-2005)		
		CA2545435C	19 August 2014 (19-08-2014)		
		CN1901907A	24 January 2007 (24-01-2007)		
		CN1906162A	31 January 2007 (31-01-2007)		
		CN1906162B	23 May 2012 (23-05-2012)		
		EP1682134A2	26 July 2006 (26-07-2006)		
		EP1682134A4	15 October 2008 (15-10-2008)		
		EP1682504A2	26 July 2006 (26-07-2006)		
		EP1682504A4	22 October 2008 (22-10-2008)		
		EP1682504B1	26 December 2012 (26-12-2012)		
		ES2402182T3	29 April 2013 (29-04-2013)		
		IL175444D0	05 September 2006 (05-09-2006)		
		IL175444A	30 May 2013 (30-05-2013)		
		IL175472D0	05 September 2006 (05-09-2006)		
		JP2007512253A	17 May 2007 (17-05-2007)		
		JP4767172B2	07 September 2011 (07-09-2011)		
		JP2007510753A	26 April 2007 (26-04-2007)		
		US2005130972A1	16 June 2005 (16-06-2005)		
		US7741340B2	22 June 2010 (22-06-2010)		
		US2005137223A1	23 June 2005 (23-06-2005)		
		US2010189708A1	29 July 2010 (29-07-2010)		
		WO2005046611A2	26 May 2005 (26-05-2005)		
		WO2005046611A3	09 September 2005 (09-09-2005)		
		WO2011049736A1	28 April 2011 (28-04-2011)	WO2011049736A1	28 April 2011 (28-04-2011)
				AR078606A1	23 November 2011 (23-11-2011)
AU2010308396A1	03 May 2012 (03-05-2012)				
CA2778348A1	28 April 2011 (28-04-2011)				
CN102655747A	05 September 2012 (05-09-2012)				
EP2490532A1	29 August 2012 (29-08-2012)				
EP2490532A4	12 June 2013 (12-06-2013)				
IL219160D0	28 June 2012 (28-06-2012)				
JP2013508366A	07 March 2013 (07-03-2013)				
KR20120104549A	21 September 2012 (21-09-2012)				
MX2012004548A	04 July 2012 (04-07-2012)				
RU2012120759A	27 November 2013 (27-11-2013)				
TW201116279A	16 May 2011 (16-05-2011)				
US2011092541A1	21 April 2011 (21-04-2011)				
US8604206B2	10 December 2013 (10-12-2013)				
US2014080871A1	20 March 2014 (20-03-2014)				
WO2013075227A1	30 May 2013 (30-05-2013)	None			